On this page
Quick Reference
Overview and Recommendations
Background
- •Recognize diabetic nephropathy as a clinical syndrome arising from long-standing diabetes, traditionally defined by the progression from glomerular hyperfiltration to microalbuminuria (30–300 mg/day), overt macroalbuminuria (>300 mg/day), and eventually end-stage renal disease.
- •Distinguish between the classic albuminuric phenotype and the non-albuminuric phenotype; the latter is increasingly common in and is characterized by a declining eGFR (<60 mL/min/1.73m²) without significant albuminuria, often reflecting tubulointerstitial or macrovascular aging rather than pure glomerular injury.
- •Understand the Mogensen stages of progression, which begin with Stage 1 (Hyperfiltration, GFR >140 mL/min/1.73m²) and Stage 2 (Silent stage with structural changes like basement membrane thickening), before progressing to clinically detectable Stage 3 (Incipient nephropathy) and Stage 4 (Overt nephropathy).
- •Identify the systemic nature of the disease through the lens of Metabolic Cardiovascular Renal Disease (Met-CVRD), which highlights the bidirectional relationship between the heart and kidneys mediated by chronic low-grade inflammation, mitochondrial dysfunction, and metabolic instability.
- •Note the significant epidemiological burden, as approximately 30-40% of individuals with diabetes will develop chronic kidney disease, which serves as a potent multiplier for premature mortality and cardiovascular events.
Evaluation
- •Screen all patients with type 2 diabetes at the time of diagnosis and patients with type 1 diabetes five years after diagnosis, using both the urinary albumin-to-creatinine ratio (UACR) and the (eGFR).
- •Confirm the diagnosis of persistent albuminuria by obtaining at least two elevated UACR samples (≥30 mg/g) over a three-to-six-month period, as transient elevations can occur due to exercise, infection, or heart failure.
- •Perform a comprehensive fundoscopic examination or optical coherence tomography (OCT) to screen for ; the presence of proliferative retinopathy or hard exudates is a strong clinical predictor of concurrent diabetic nephropathy and rapid eGFR decline.
- •Assess for metabolic and anthropometric risk factors beyond BMI, specifically measuring the Visceral Fat Area (VFA) or calculating the Metabolic Score for Visceral Fat (METS-VF), as visceral adiposity is a more potent driver of renal decline than subcutaneous fat.
- •Evaluate glycemic stability by reviewing HbA1c variability and continuous glucose monitoring (CGM) metrics, specifically the Time in Range (TIR; 70–180 mg/dL), as high glucose fluctuations trigger repetitive bouts of oxidative stress that damage the renal microvasculature.
- •Order serum uric acid (SUA) levels, as even high-normal levels are independently associated with early impaired kidney function and may necessitate more aggressive monitoring.
- •Suspect non-diabetic kidney disease (NDKD) if the patient presents with "red flags" such as the absence of retinopathy (especially in type 1 diabetes), sudden onset of nephrotic syndrome, active urinary sediment (dysmorphic red cells or casts), or a rapid decline in eGFR (>5 mL/min/1.73m²/year).
- •Utilize the ELIXA risk score—incorporating age, BMI, HbA1c, systolic blood pressure, lipids, smoking status, and retinopathy—to categorize patients into low, moderate, high, or very high-risk groups for cardiorenal outcomes.
- •Measure B-type natriuretic peptide (BNP) levels; high-normal levels (>14.5 pg/mL) can predict eGFR decline independent of baseline albuminuria and provide incremental prognostic value.
- •Consider a renal biopsy only when clinical features are atypical for diabetic nephropathy to rule out primary glomerulonephritides like or , which may require immunosuppressive therapy.
Management
- •Initiate foundational therapy with the maximum tolerated dose of an (e.g., Lisinopril 10–40 mg daily) or an (e.g., Losartan 50–100 mg daily) for all patients with hypertension and albuminuria to reduce intraglomerular pressure.
- •Administer an SGLT2 inhibitor (e.g., Dapagliflozin 10 mg daily or Empagliflozin 10 mg daily) as first-line therapy for patients with an eGFR ≥20–25 mL/min/1.73m², regardless of glycemic control, to provide potent nephroprotection and reduce the risk of heart failure.
- •Add a non-steroidal mineralocorticoid receptor antagonist (ns-MRA), specifically Finerenone 10 mg or 20 mg daily, for patients with persistent albuminuria (UACR ≥30 mg/g) despite optimized ACEi/ARB and SGLT2i therapy, provided serum potassium is ≤4.8 mEq/L.
- •Incorporate a GLP-1 receptor agonist (e.g., Semaglutide 1 mg weekly SC) for patients with high cardiovascular risk or persistent albuminuria, as these agents significantly reduce major kidney events and all-cause mortality.
- •Target a blood pressure of <130/80 mmHg for most patients, though an intensive target of <120 mmHg may be considered if it can be achieved without significant adverse effects like acute kidney injury or hyperkalemia.
- •Optimize lipid management using high-intensity (e.g., Atorvastatin 40–80 mg daily) to achieve an LDL-C target of <55 mg/dL (1.4 mmol/L), given the extreme cardiovascular risk associated with diabetic kidney disease.
- •Monitor serum potassium closely, especially when combining RAAS inhibitors and Finerenone; use potassium binders if necessary to maintain levels <5.0 mmol/L and avoid the premature discontinuation of life-saving nephroprotective agents.
- •Implement nutritional interventions focused on a high Oxidative Balance Score (OBS), encouraging a diet rich in antioxidants (e.g., Mediterranean or DASH diet) and smoking cessation to reduce systemic oxidative stress.
- •Avoid the use of dual RAAS blockade (combining an ACEi and an ARB) due to the significantly increased risk of hyperkalemia and acute kidney injury without additional benefit.
- •Refer to a nephrologist when the eGFR falls below 30 mL/min/1.73m², when there is a rapid decline in renal function, or when the etiology of the kidney disease is uncertain.
- •Prepare for renal replacement therapy (RRT) when eGFR approaches <15–20 mL/min/1.73m², prioritizing kidney transplantation or integrated endocrinology-transplant care to optimize post-transplant metabolic outcomes.
- •Utilize Continuous Glucose Monitoring (CGM) for patients on dialysis to assess glycemic control, as HbA1c becomes increasingly unreliable in the setting of advanced uremia and altered red blood cell turnover.
Board Review — High Yield
- •Kimmelstiel-Wilson nodules — Pathognomonic histopathological finding of intercapillary glomerulosclerosis in diabetic nephropathy.
- •Hyperfiltration — The earliest functional change in DN, driven by afferent arteriolar dilation (SGLT2-mediated) and efferent constriction (RAAS-mediated).
- •Non-albuminuric DKD — A phenotype where eGFR declines without significant proteinuria, more common in Type 2 Diabetes and associated with macrovascular disease.
- •Finerenone — A non-steroidal MRA that provides anti-inflammatory/anti-fibrotic benefits with less hyperkalemia than spironolactone.
- •Eye-Kidney Axis — The high correlation between diabetic retinopathy and nephropathy; retinopathy is nearly always present in Type 1 diabetics with DN.
- •Metabolic Memory — The phenomenon where early glycemic control provides long-term protection against complications, mediated by the NAD+-SIRT3 axis.
- •SGLT2i Mechanism — Restores tubuloglomerular feedback by increasing sodium delivery to the macula densa, leading to afferent arteriolar vasoconstriction.
Deep Dive — Evidence Details
Definition, Synonyms, and Classification
- ▸Diabetic nephropathy is defined by persistent albuminuria (>300 mg/day) and a progressive decline in GFR, though non-albuminuric variants are increasingly recognized.
- ▸The nomenclature is shifting from 'Diabetic Nephropathy' to 'Diabetic Kidney Disease' (DKD) and 'Metabolic Dysfunction-Associated Kidney Disease' (MDAKD) to reflect broader metabolic etiologies.
- ▸Progression follows five stages (Mogensen), moving from early hyperfiltration to incipient microalbuminuria, overt macroalbuminuria, and finally end-stage renal disease.
Diabetic nephropathy (DN) is a clinical syndrome characterized by persistent albuminuria, a progressive decline in the (GFR), and elevated arterial blood pressure, occurring as a direct consequence of long-standing [3]D[6]D[10]D. Historically, the term was reserved for patients with biopsy-proven glomerular lesions, but it is now frequently used interchangeably with the broader clinical designation of (DKD) [6]D. Approximately 30% or more of individuals diagnosed with diabetes will develop chronic kidney disease (CKD), which significantly increases the risk of premature mortality and the eventual need for renal replacement therapy [1][10]D.
Evolution of Nomenclature
The terminology surrounding kidney disease in diabetes has evolved to reflect a more nuanced understanding of its pathogenesis. While "diabetic nephropathy" traditionally implied a specific histopathological progression (e.g., Kimmelstiel-Wilson nodules), the term "diabetic kidney disease" (DKD) is now preferred for a clinical diagnosis based on reduced GFR or albuminuria in the setting of diabetes [6]D[10]D.
Recent shifts in nomenclature emphasize the role of metabolic dysfunction as a primary driver. The term Metabolic Dysfunction-Associated Kidney Disease (MDAKD) has been proposed to describe CKD arising from metabolic abnormalities such as obesity, insulin resistance, and dyslipidemia, often occurring within the context of metabolic syndrome [2]D. Furthermore, the concept of Metabolic Cardiovascular Renal Disease (Met-CVRD) has emerged to highlight the bidirectional and metabolically driven relationship between the heart and kidneys, mediated by chronic low-grade inflammation and mitochondrial abnormalities [4]D.
Synonyms and Alternate Names
- Diabetic Kidney Disease (DKD): The current preferred clinical term [6]D.
- Kimmelstiel-Wilson Syndrome: An older eponym referring specifically to intercapillary glomerulosclerosis.
- Metabolic Dysfunction-Associated Kidney Disease (MDAKD): Emphasizes the role of obesity and metabolic syndrome [2]D.
- Metabolic Cardiovascular Renal Disease (Met-CVRD): Highlights the systemic nature of the metabolic-renal-cardiac axis [4]D.
- ICD-10 Classifications: Often coded as N08.3 (Glomerular disorders in diabetes) or E10.2/E11.2 (Diabetes with kidney complications) [8]D.
Phases and Stages of Progression
The progression of diabetic nephropathy is classically described through five distinct stages, often referred to as the Mogensen stages. These stages track the transition from early functional changes to end-stage renal disease (ESRD).
- Stage 1: Hyperfiltration (Prodromal Phase): Characterized by an increased GFR (often >140 mL/min/1.73m²) and renal hypertrophy. This is a functional stage where the kidneys overwork in response to hyperglycemia [3]D.
- Stage 2: Silent Stage (Structural Changes): The GFR may return to normal, but histological changes such as basement membrane thickening and mesangial expansion begin to occur. Albumin excretion remains within the normal range (<30 mg/day) [10]D.
- Stage 3: Incipient Nephropathy (Progressive Phase): Defined by the onset of microalbuminuria (30–300 mg/day). This stage is a critical turning point where intervention can significantly delay progression [10]D.
- Stage 4: Overt Nephropathy (Plateau of Proteinuria): Characterized by macroalbuminuria (>300 mg/day) and a steady decline in GFR. becomes nearly universal in this stage due to the activation of the renin-angiotensin-aldosterone (RAA) axis [7]D[10]D.
- Stage 5: End-Stage Renal Disease (Nadir of Function): The point where the GFR falls below 15 mL/min/1.73m², necessitating dialysis or transplantation. This represents the "nadir" of renal function [8]D[10]D.
Classification of Variants
Not all patients with diabetes follow the classic albuminuric pathway. Modern classification recognizes the heterogeneity of the disease, particularly the distinction between albuminuric and non-albuminuric phenotypes [10]D.
| Variant Name | Key Distinguishing Feature | Clinical Context |
|---|---|---|
| Classic Albuminuric DN | Progressive increase in albuminuria followed by GFR decline. | Most common in Type 1 Diabetes (T1D) and many Type 2 (T2D) cases [8]D. |
| Non-Albuminuric DKD | GFR <60 mL/min/1.73m² without significant albuminuria. | Increasingly recognized in T2D; often associated with macrovascular disease [10]D. |
| MDAKD | Kidney disease driven by obesity and insulin resistance. | Occurs in patients with metabolic syndrome, even with mild hyperglycemia [2]D. |
| Met-CVRD | Integrated heart-kidney failure with metabolic triggers. | Characterized by ectopic lipid deposition and chronic inflammation [4]D. |
Clinical Reasoning for Classification
The distinction between these types is vital because the underlying mechanisms differ. For instance, classic DN is heavily driven by glomerular hemodynamic changes and the RAA axis, making ACE inhibitors (e.g., Lisinopril 10 mg daily) or ARBs (e.g., Losartan 50 mg daily) the standard of care to reduce intraglomerular pressure [7]D. In contrast, the non-albuminuric phenotype may reflect more prominent tubulointerstitial or vascular aging rather than pure glomerular injury [10]D. Furthermore, patients with DN are at increased risk for systemic complications, including unusual infections such as Dysgonomonas mossii, due to the combined effects of chronic uremia and diabetes-induced immunosuppression [5]C.
| Stage | Description | Albuminuria Level | GFR Status |
|---|---|---|---|
| Stage 1 | Hyperfiltration | Normal (<30 mg/24h) | Increased (>140 mL/min) |
| Stage 2 | Silent Stage | Normal (<30 mg/24h) | Normal |
| Stage 3 | Incipient DN | Microalbuminuria (30-300 mg/24h) | Stable or slightly decreased |
| Stage 4 | Overt DN | Macroalbuminuria (>300 mg/24h) | Progressively decreasing |
| Stage 5 | ESRD | Variable (may decrease) | <15 mL/min |
Epidemiology and Risk Factors
- ▸The prevalence of DKD in T2DM populations is approximately **37.9%**, with **34.6%** of patients exhibiting albuminuria [40].
- ▸Glycemic variability and Time in Range (TIR) are more sensitive predictors of renal risk than static HbA1c measurements [13, 40].
- ▸Visceral adiposity (VFA) and metabolic indices like TyG-BMI are superior to BMI for predicting DKD risk [19, 23, 29].
(DKD), also known as diabetic nephropathy, is a prevalent microvascular complication of and remains the leading cause of (ESRD) globally [11][14]. Despite improvements in clinical , the incidence and prevalence of DKD continue to escalate, presenting a significant public health challenge [11]. In contemporary cohorts of patients with (T2DM), the prevalence of albuminuria is approximately 34.6%, while the overall prevalence of DKD reaches 37.9% [40]D.
Global Burden and Temporal Trends
The rising incidence of DKD is closely linked to the global diabetes epidemic [17]. While traditional risk factors like chronic hyperglycemia and are well-established, recent data suggest that the burden of DKD is shifting due to aging populations and the increasing prevalence of obesity [16][24]. In specific populations, such as the US Veterans, efficient risk stratification is becoming critical for resource allocation and cost-effectiveness [28]D. Furthermore, the landscape of clinical trials, particularly in regions like China, reflects a rapid evolution in the understanding of DKD , moving from bioequivalence studies to the evaluation of novel agents like SGLT2 inhibitors and GLP-1 receptor agonists [17].
Glycemic Determinants and Variability
While mean (HbA1c) is a standard marker for risk, recent evidence emphasizes that glycemic stability is equally critical. HbA1c variability is significantly associated with an increased risk of DKD progression [13][39]D. This is likely because fluctuations in glucose levels trigger repetitive bouts of , which are more damaging to the renal microvasculature than stable hyperglycemia [21][27].
Modern metrics derived from continuous glucose monitoring (CGM) provide deeper insights into risk. Time in Range (TIR; 70–180 mg/dL) and Time in Tight Range (TITR; 70–140 mg/dL) are inversely associated with DKD risk; higher TITR and TIR significantly reduce the odds of developing albuminuria [40]D. Conversely, a high acute-to-chronic glycemic ratio (ACG ratio) serves as a biomarker for poor prognosis in diabetic complications [22].
Metabolic and Anthropometric Risk Factors
Obesity and visceral adiposity are potent drivers of renal decline. The Visceral Fat Area (VFA) and the Metabolic Score for Visceral Fat (METS-VF) are more predictive of DKD than simple body mass index (BMI) [19][29]D. Visceral fat is metabolically active, secreting pro-inflammatory cytokines that promote mesangial expansion and tubulointerstitial fibrosis [35]D[36]D.
Other metabolic markers include:
- Serum Uric Acid (SUA): Elevated SUA levels are independently correlated with an increased risk of DKD in T2DM patients [15]. Even in newly diagnosed patients with "normal" SUA, higher levels within the normal range are associated with early impaired kidney function [26].
- Lipoprotein-associated Phospholipase A2 (Lp-PLA2): High levels of Lp-PLA2 are associated with a significantly higher risk of DKD, with an OR of 1.01 [12].
- Triglyceride-Glucose BMI (TyG-BMI) Index: This index, a surrogate for insulin resistance, is an independent risk factor with an OR of 1.019 [23].
Cardiovascular and Hemodynamic Influences
Hypertension is both a cause and a consequence of DKD. A family history of hypertension significantly increases the odds of developing DKD in individuals with T2DM, suggesting a shared genetic or environmental predisposition [33]D. The association between blood pressure and renal outcomes is age-specific; systolic blood pressure (SBP) remains a critical indicator across all age groups, but its impact on the risk of varies by baseline age [24]. Furthermore, the presence of other microvascular or macrovascular complications, such as or cardiac , serves as a strong predictor for concurrent renal involvement [16][38]D.
Non-Modifiable Factors and Genetics
- Duration of Diabetes: The cumulative metabolic exposure over time is a primary driver. Each year of diabetes duration increases the risk of DKD with an OR of 1.037 [23][32]D.
- Genetics: Approximately 8% of patients with T2DM carry diagnostic variants for Mendelian kidney disease [30]D. While these variants contribute to the overall risk, they do not always distinguish between diabetic and non-diabetic causes of chronic kidney disease [30]D.
- Sex and Ethnicity: Visceral fat associations with DKD risk exhibit sex-specific patterns, often showing stronger correlations in specific demographic subgroups [19][34]D.
Protocol for Epidemiological Risk Stratification
Clinicians should follow a systematic approach to identify high-risk patients before the onset of overt :
- Step 1: Baseline Clinical Assessment — Evaluate the duration of diabetes (OR 1.037 per year), family history of hypertension, and presence of [16][23][33]D.
- Step 2: Metabolic Profiling — Measure visceral adiposity (VFA or METS-VF) and serum uric acid levels [15][19][29]D.
- Step 3: Glycemic Stability Review — Analyze HbA1c variability and, if available, CGM metrics such as Time in Range (TIR) [13][40]D.
- Step 4: Advanced Biomarker Integration — Consider novel markers like Lp-PLA2 or the FIB-4 index to refine the risk of renal function deterioration [12][20].
| Risk Factor | Association/Effect Size | Evidence Level |
|---|---|---|
| Diabetes Duration | OR 1.037 (95% CI: 1.005–1.07) | 2b [23] |
| Lp-PLA2 Levels | OR 1.01 (95% CI: 1.01–1.02) | 2a [12] |
| TyG-BMI Index | OR 1.019 (95% CI: 1.007–1.030) | 2b [23] |
| Serum Uric Acid | Significant positive correlation | 2a [15] |
| HbA1c Variability | Significant risk for progression | 2a [13] |
| Visceral Fat (VFA) | Significant sex-specific risk | 2b [19] |
| Metric | Definition | Impact on DKD Risk |
|---|---|---|
| TIR | Time in Range (70–180 mg/dL) | Higher TIR reduces odds of albuminuria [40]D |
| TITR | Time in Tight Range (70–140 mg/dL) | Higher TITR reduces odds of DKD [40]D |
| HbA1c Variability | Visit-to-visit fluctuation | High variability increases risk of ESRD [13][27] |
| ACG Ratio | Acute-to-chronic glycemic ratio | High ratio predicts poor complication prognosis [22] |
Etiology and Triggering Factors
- ▸HbA1c variability is an independent trigger for DKD progression, often carrying more prognostic weight than static HbA1c levels alone.
- ▸Visceral adiposity and BMI variability ('metabolic cycling') are more predictive of renal decline than absolute BMI.
- ▸The risk of kidney impairment begins in the prediabetic range (HbA1c 5.7%–6.4%), necessitating early screening.
Diabetic nephropathy (DN), also termed (DKD), is a multi-factorial microvascular complication primarily driven by chronic hyperglycemia that initiates a cascade of hemodynamic, metabolic, and inflammatory pathways leading to progressive glomerular and tubulointerstitial damage [47]D[51]D. While absolute glycemic levels are critical, recent evidence emphasizes that the variability of metabolic markers and the cumulative burden of the cardiovascular-kidney-metabolic (CKM) syndrome are equally significant in disease initiation [13][47]D.
Metabolic and Glycemic Triggers
Chronic hyperglycemia is the fundamental driver of DKD, but the risk begins even before the formal diagnosis of diabetes. Individuals with (HbA1c 5.7%–6.4%) exhibit a significantly higher risk of developing early kidney impairment, characterized by a decline in estimated glomerular filtration rate (eGFR) and increased albuminuria [49]D.
Beyond mean HbA1c, HbA1c variability (visit-to-visit fluctuations) is an independent risk factor for both the development and progression of DKD [13][39]D. High variability suggests a state of "metabolic instability" that may exacerbate oxidative stress and endothelial dysfunction more severely than stable, albeit elevated, glucose levels [13]. Furthermore, markers of insulin resistance, such as the triglyceride-glucose (TyG) index and its derivatives (TyG-BMI), serve as potent predictors of renal decline in both type 1 and type 2 diabetes [44][51]D. These indices reflect the systemic metabolic environment that promotes lipid-induced renal injury (lipotoxicity) [51]D.
Hemodynamic and Vascular Factors
Systemic is both a cause and a consequence of DKD. A family history of hypertension significantly increases the odds of developing DKD, suggesting a genetic predisposition to vascular pressure sensitivity [33]D. The impact of blood pressure (BP) is age-specific; for instance, the association between elevated systolic BP and incident CKD is particularly robust in younger adults (18–44 years) compared to older populations, where arterial stiffness may confound readings [24].
Adiposity and Visceral Fat Distribution
Obesity contributes to DKD through the CKM syndrome, where dysfunctional adipose tissue promotes chronic systemic inflammation [47]D. Recent studies highlight that visceral fat area (VFA) and the Body Roundness Index (BRI) are superior to BMI in predicting renal risk [19][36]D. Visceral adiposity acts as an endocrine organ, secreting pro-inflammatory cytokines that directly damage the glomerular filtration barrier [19][29]D.
Furthermore, BMI variability, or "metabolic cycling," has emerged as a critical trigger. In type 1 diabetes, frequent fluctuations in body weight are associated with a higher risk of ≥ 50% eGFR decline, potentially due to repeated shifts in metabolic demand and inflammatory signaling [34]D.
Inflammatory and Oxidative Stress Pathways
Chronic low-grade inflammation is a hallmark of DKD. Elevated white blood cell (WBC) counts and high levels of serum uric acid (SUA) are independent predictors of early impaired kidney function [15][23]. Uric acid may induce renal injury via the activation of the renin-angiotensin-aldosterone system (RAAS) and the induction of endothelial dysfunction [15][26].
Conversely, a high Oxidative Balance Score (OBS)—representing a lifestyle rich in antioxidants and low in pro-oxidants—is protective [21]. This suggests that dietary patterns and lifestyle-associated oxidative stress are modifiable triggers that dictate the rate of microvascular deterioration [21][45].
Comorbidities and Systemic Crosstalk
DKD is increasingly viewed through the lens of multi-organ crosstalk:
- Obstructive Sleep Apnea (OSA): A bidirectional relationship exists where OSA-induced intermittent hypoxia exacerbates renal oxidative stress, while CKD-related fluid overload can worsen airway obstruction [41].
- Liver-Kidney Axis: The FIB-4 index, a marker of liver fibrosis, is independently associated with the prevalence of DKD, suggesting shared pathways of fibrogenesis [20].
- Autonomic Dysfunction: Cardiac (CAN) often co-occurs with nephropathy, with SUDOSCAN-derived scores showing a strong correlation between sudomotor dysfunction and renal risk [38]D.
Genetic and Pharmacological Modifiers
Genetic susceptibility is modified by drug-gene interactions (DGIs). Specific genotypes can alter the safety and efficacy of common medications, potentially increasing the risk of microvascular complications if the drug metabolism is suboptimal [42]. Additionally, the choice of insulin therapy may influence outcomes; long-acting insulin analogues have been associated with a lower risk of incident nephropathy compared to NPH insulin in some cohorts, likely due to reduced glycemic variability [43].
Risk Stratification Protocol
Clinicians should follow this protocol to identify high-risk patients based on etiological triggers:
- Step 1: Baseline Metabolic Assessment → Measure HbA1c, UACR, and eGFR. Calculate the TyG index and assess for prediabetes (HbA1c 5.7%–6.4%) [44][49]D[51]D.
- Step 2: Adiposity and Lifestyle Review → Evaluate visceral fat (VFA or BRI) rather than BMI alone. Calculate the Oxidative Balance Score based on diet and smoking status [19][21][36]D.
- Step 3: Comorbidity Screening → Screen for OSA, hypertension (including family history), and liver fibrosis (FIB-4 index) to identify systemic contributors to renal decline [20][33]D[41].
| Cause / Trigger | Category | Mechanism | Associated Subtype | Key Reference |
|---|---|---|---|---|
| HbA1c Variability | Metabolic | Fluctuating glucose levels increase oxidative stress and endothelial damage. | T1DM & T2DM | [13], [39]D |
| Visceral Adiposity | Metabolic/Inflammatory | Secretion of pro-inflammatory adipokines and CKM syndrome activation. | T2DM (High VFA/BRI) | [19], [29]D, [36]D |
| Serum Uric Acid | Metabolic/Vascular | RAAS activation and induction of endothelial dysfunction. | Early EIKF | [15], [26] |
| TyG Index | Metabolic | Surrogate for insulin resistance and lipid-induced renal lipotoxicity. | T1DM & T2DM | [44], [51]D |
| Obstructive Sleep Apnea | Respiratory/Systemic | Intermittent hypoxia-induced oxidative stress and sympathetic activation. | T2DM | [41] |
| Family History of HTN | Genetic/Hemodynamic | Inherited predisposition to glomerular hyperfiltration and pressure injury. | T2DM | [33]D |
| FIB-4 Index | Systemic | Liver-kidney axis crosstalk and shared fibrotic pathways. | T2DM | [20] |
| BMI Variability | Metabolic | 'Metabolic cycling' promoting recurrent inflammatory surges. | T1DM | [34]D |
| Remnant Cholesterol | Lipid/Vascular | Pro-atherogenic lipids contributing to microvascular damage. | Biopsy-proven DKD | [50]D |
| Drug-Gene Interactions | Genetic | Genotype-specific variations in drug metabolism affecting renal safety. | T2DM | [42] |
Pathophysiology
- ▸Diabetic nephropathy is driven by a 'metabolic memory' effect where the NAD+-SIRT3 axis maintains oxidative stress and epigenetic changes even after glucose normalization [55].
- ▸Glomerular hyperfiltration, mediated by RAAS and tubuloglomerular feedback, is the primary hemodynamic driver of early structural damage [66, 73].
- ▸Intercellular crosstalk via extracellular vesicles and myokines (like IL-15) plays a critical role in maintaining or disrupting podocyte integrity [72, 79].
The development of diabetic nephropathy (DN), also known as (DKD), is a multi-staged process driven by a complex interplay of hemodynamic, metabolic, and inflammatory dysregulation [61]D. While chronic hyperglycemia serves as the primary initiating insult, the progression to end-stage renal disease (ESRD) involves a cascade of molecular events including oxidative stress, mitochondrial dysfunction, and epigenetic reprogramming [55]D[64]D.
Hemodynamic Alterations and Hyperfiltration
Early DN is characterized by glomerular hyperfiltration, a state of increased filtration capacity that precedes clinical albuminuria [73]D. This process is largely driven by the activation of the renin-angiotensin-aldosterone system (RAAS), which increases intraglomerular pressure [61]D[66]D.
Step-by-step Hemodynamic Mechanism:
- Hyperglycemia leads to increased glucose reabsorption in the proximal tubule via SGLT2, which is coupled with sodium reabsorption [66]D.
- Decreased sodium delivery to the macula densa triggers tubuloglomerular feedback, causing afferent arteriolar vasodilation [66]D.
- Simultaneous RAAS activation causes efferent arteriolar vasoconstriction, resulting in elevated intraglomerular capillary pressure [61]D.
- Sustained high pressure leads to mechanical stretch of the glomerular basement membrane (GBM) and podocyte foot process effacement [57]D[73]D.
Metabolic Signaling and Molecular Pathways
Hyperglycemia triggers several intracellular pathways that promote renal injury. The accumulation of advanced glycation end products (AGEs) and the activation of the polyol pathway and protein kinase C (PKC) are central to this damage [57]D[64]D.
In youth with type 2 diabetes and obesity, the mTORC1/JAK/STAT signaling pathway has been identified as a critical driver of early kidney injury [53]. Activation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) axis promotes cellular hypertrophy and pro-inflammatory gene expression [75]D. Furthermore, post-translational modifications (PTMs), including phosphorylation, acetylation, and ubiquitination, modulate the function of key proteins involved in renal homeostasis [59]D. For example, the loss of the deubiquitinating enzyme USP46 leads to the cytosolic aggregation of TDP-43 in podocytes, accelerating glomerular lesions [77]D.
Mitochondrial Dysfunction and Metabolic Memory
Mitochondria are the central organelles for energy metabolism and play a pivotal role in DN pathogenesis [58]D. Chronic metabolic stress leads to an imbalance in mitochondrial dynamics (fission and fusion), defective mitophagy, and the release of mitochondrial DNA (mtDNA) into the cytosol [56]D.
The NAD+-SIRT3 Axis and Metabolic Memory: Metabolic memory refers to the persistent risk of complications even after achieving glycemic control [55]D. This is driven by the NAD+-SIRT3 axis. Reduced levels of nicotinamide adenine dinucleotide (NAD+) impair the activity of Sirtuin 3 (SIRT3), a mitochondrial deacetylase [55]D. This impairment leads to:
- Sustained oxidative stress through increased reactive oxygen species (ROS) production [55]D[67]D.
- Epigenetic reprogramming that maintains pro-inflammatory states [55]D.
- Impaired mitochondrial biogenesis and organelle crosstalk, particularly at mitochondria-ER contacts (MAMs) [56]D.
Inflammatory Cascade and Immune Activation
DN is increasingly recognized as a chronic inflammatory condition [60]D. Early stages involve the infiltration of the renal interstitium by macrophages, T-cells, B-cells, and dendritic cells [60]D.
Key Inflammatory Mediators:
- NF-κB and NLRP3: These pathways integrate metabolic signals to trigger the release of pro-inflammatory cytokines [62]D[64]D.
- Adipokines: Bioactive proteins like ANGPTL4 and adiponectin modulate systemic inflammation and lipid overload in the kidney [57]D[62]D.
- Soluble Guanylate Cyclase (sGC): Impaired sGC signaling reduces cyclic guanosine monophosphate (cGMP) levels, promoting vasoconstriction and fibrosis [63]D.
Structural Remodeling and Cellular Crosstalk
Progressive DN results in characteristic structural changes: GBM thickening, mesangial expansion, and podocyte loss [57]D[77]D. Intercellular communication is vital in this process. Extracellular vesicles (EVs) secreted by mesangial cells under high-glucose conditions (e.g., 30 mM HG) can induce epithelial-mesenchymal transition (EMT) in healthy podocytes, upregulating markers like desmin and TGF-β1 [79]D.
Podocyte health is also influenced by muscle-kidney crosstalk; for instance, the myokine IL-15 helps preserve podocyte mitochondrial fusion, while its deficiency exacerbates injury [72]D. In the later stages, oxidative stress-induced ferroptosis (iron-dependent programmed cell death) in tubular epithelial cells further drives renal fibrosis [68]D[71]D[78]D.
Susceptibility and Environmental Factors
Not all diabetic patients develop DN, suggesting immunogenetic and environmental modifiers. Environmental toxicants, such as Aflatoxin B1 (AFB1), can accelerate progression by activating the ITGA11/LTBP1 pathway, which enhances oxidative and fibrotic injury [80]D. Lifestyle factors also influence the oxidative balance score (OBS); a lower OBS (indicating higher oxidative stress) is associated with a significantly higher risk of microvascular complications [21].
| Mediator/Pathway | Target Cell/Organelle | Pathological Effect |
|---|---|---|
| JAK/STAT | Glomerular cells | Cellular hypertrophy and inflammation [53][75]D |
| SIRT3 | Mitochondria | Regulates ROS and metabolic memory [55]D |
| USP46 | Podocytes | Prevents TDP-43 aggregation and podocyte loss [77]D |
| Nrf2 | Endothelium/Tubules | Master regulator of antioxidant defense; often suppressed [64]D[69]D[71]D |
| TGF-β | Mesangium/Interstitium | Primary driver of renal fibrosis and EMT [64]D[79]D |
| Mediator | Mechanism | Clinical Impact |
|---|---|---|
| AGEs | Non-enzymatic glycation of proteins | GBM thickening and stiffness [57]D[64]D |
| mTORC1 | Nutrient sensing and protein synthesis | Glomerular hypertrophy in obese youth [53] |
| Connexin 43 | Gap junction communication | Altered cell-cell signaling in diabetic kidneys [76]D |
| ANGPTL4 | Lipid metabolism/Inflammation | Proteinuria and impaired filtration [57]D |
| GPX4 | Ferroptosis inhibition | Reduced tubular cell death when active [68]D[69]D |
Clinical Features and Variants
- ▸Diabetic kidney disease often progresses silently, with symptoms appearing only in advanced stages of eGFR decline or nephrotic-range albuminuria.
- ▸The non-albuminuric phenotype (NADKD) accounts for a significant portion of cases, where eGFR falls below 60 mL/min/1.73 m² despite normal urinary albumin levels.
- ▸Rapid decliners are defined by an eGFR loss of > 5 mL/min/1.73 m² per year and require intensive cardiorenal risk management.
(DKD) is a progressive microvascular complication that often advances silently, characterized by a transition from hyperfiltration to and a subsequent decline in the (eGFR) [94]D. The clinical presentation varies significantly between type 1 (T1D) and type 2 diabetes (T2D), with the latter often exhibiting renal impairment at the time of diagnosis due to prolonged asymptomatic hyperglycemia [91].
Presenting Symptoms and Natural History
In its early stages, DKD is clinically silent. Patients rarely present with symptoms until the eGFR has significantly declined or albuminuria has reached nephrotic levels [94]D. The classic progression involves an initial period of glomerular hyperfiltration, followed by the development of microalbuminuria (UACR 30–299 mg/g), which may eventually progress to macroalbuminuria (UACR ≥ 300 mg/g) and end-stage kidney disease (ESKD) [91][101]D.
In children and adolescents with T1D, the onset of albuminuria is rare before age 14 or within the first two years of diagnosis [83]. Systematic reviews indicate that most cases of moderate albuminuria occur after at least seven years of diabetes duration [83]. Conversely, in T2D, the prevalence of CKD is high (approximately 27.3% in some cohorts), with many patients already manifesting an eGFR < 60 mL/min/1.73 m² or significant albuminuria at clinical presentation [91].
Clinical Assessment and Physical Findings
The physical examination focuses on identifying comorbid microvascular and macrovascular complications, as DKD rarely occurs in isolation.
- Blood Pressure: is both a cause and a consequence of DKD. Elevated systolic blood pressure (SBP) is a primary component of cardiorenal risk stratification [16].
- Ophthalmic Findings: The presence of is a strong clinical predictor of DKD, reflecting systemic microvascular damage [16].
- Volume Status: Peripheral edema may indicate advanced proteinuria or heart failure, which frequently coexists with DKD [87].
- Adiposity: High visceral fat, measured by the Metabolic Score for Visceral Fat (METS-VF), is independently associated with an increased risk of DKD [29]D.
Phenotypic Variants
Modern clinical practice recognizes that DKD is not a monolithic entity. The traditional "albuminuric" pathway is increasingly supplemented by the "non-albuminuric" phenotype.
| Variant | Key Features | Clinical Significance |
|---|---|---|
| Albuminuric DKD (ADKD) | Classic presentation; UACR ≥ 30 mg/g; progressive podocyte injury [77]D[99]D. | High risk of progression to ESKD and cardiovascular events [100]D. |
| Non-albuminuric DKD (NADKD) | eGFR < 60 mL/min/1.73 m² with persistent UACR < 30 mg/g [48][96]. | Often associated with macrovascular disease and aging; requires SGLT2i/ARB therapy [96]. |
| Rapid Decliners | Annualized eGFR loss > 5 mL/min/1.73 m²/year [48][104]D. | Requires aggressive intervention; associated with higher baseline HbA1c and BNP [48][85]. |
| Regression Phenotype | Reduction in UACR (e.g., from macro- to micro- or normoalbuminuria) [92][93]. | Often induced by intensive therapy with finerenone or SGLT2 inhibitors [92]. |
Red Flags and Risk Stratification
Clinicians must identify patients at high risk for rapid progression or cardiovascular mortality. The ELIXA risk score utilizes nine indicators—age, BMI, HbA1c, SBP, HDL, triglycerides, smoking status, retinopathy, and heart rate—to categorize patients into risk groups [16].
Critical Thresholds for Urgent Action:
- Rapid eGFR Decline: A drop of > 5 mL/min/1.73 m²/year identifies "rapid decliners" who are at imminent risk of ESKD [48][104]D.
- Macroalbuminuria: UACR ≥ 300 mg/g is associated with a significantly lower hemoglobin-to-red blood cell distribution width ratio (HRR), signaling high systemic inflammation [101]D.
- Elevated BNP: High-normal levels of B-type natriuretic peptide (> 14.5 pg/mL) predict eGFR decline independent of albuminuria levels [85].
- Inflammatory Markers: Elevated serum TNFR1 and TNFR2 are early indicators of renal inflammation, particularly in patients with low HDL cholesterol [103]D.
Atypical Presentations
While most DKD follows a predictable course, atypical features should prompt consideration of non-diabetic kidney disease (NDKD) or mixed etiology:
- Absence of Retinopathy: Especially in T1D, the absence of retinopathy in a patient with heavy proteinuria suggests an alternative diagnosis [16].
- Sudden Onset Proteinuria: DKD typically progresses gradually; sudden nephrotic syndrome may indicate or .
- Rapidly Rising Creatinine: While "rapid decliners" exist, an acute rise in creatinine should be evaluated for acute kidney injury (AKI) or rapidly progressive glomerulonephritis.
- Silent NADKD: In approximately 24% of rapid decliners, albuminuria remains absent, making eGFR monitoring the only way to detect progression [48].
| Phenotype | Diagnostic Criteria | Pathophysiological Driver |
|---|---|---|
| Albuminuric (ADKD) | UACR ≥ 30 mg/g | Podocyte injury and glomerular basement membrane thickening [77]D[99]D |
| Non-albuminuric (NADKD) | eGFR < 60 mL/min/1.73 m² AND UACR < 30 mg/g | Tubulointerstitial fibrosis and macrovascular involvement [48][96] |
| Rapid Decliner | eGFR loss > 5 mL/min/1.73 m²/year | High glycemic variability and systemic inflammation [48][104]D |
| Early DKD | Hyperfiltration or microalbuminuria | Increased intraglomerular pressure and metabolic stress [86][98] |
Diagnosis and Workup
- ▸Diagnosis requires persistent albuminuria (UACR ≥ 30 mg/g) or reduced eGFR (< 60 mL/min/1.73 m²) for at least 3 months.
- ▸The 'Eye-Kidney Axis' makes the presence of diabetic retinopathy a key clinical surrogate for the diagnosis of diabetic nephropathy.
- ▸Emerging biomarkers like BNP, MHR, and urinary isoleucine provide prognostic value beyond traditional creatinine and albumin measurements.
The diagnosis of (DKD) is primarily clinical, based on the presence of persistent albuminuria and/or a reduced estimated glomerular filtration rate (eGFR) in the setting of long-standing diabetes mellitus [11][29]D. Because DKD is a leading cause of end-stage renal disease (ESRD) worldwide, early detection through systematic screening is essential to mitigate the risk of progression [11][116]D. The diagnostic process involves confirming the presence of renal damage, excluding non-diabetic kidney diseases (NDKD), and stratifying the patient's risk for future decline using clinical and biochemical markers [16][121]D.
Diagnostic Criteria
Formal diagnosis of DKD requires the presence of at least one of the following criteria in a patient with diabetes, typically persisting for more than 3 months [29]D:
- Albuminuria: Defined as a urinary albumin-to-creatinine ratio (UACR) ≥ 30 mg/g [29]D. UACR is the preferred measurement in clinical guidelines and risk-prediction models because of its strong association with long-term kidney failure risk [119]D.
- Impaired eGFR: Defined as an eGFR < 60 mL/min/1.73 m² [29]D.
Diagnosis is often presumptive in patients with a long duration of diabetes and the presence of , which serves as a strong indicator of systemic microvascular damage [107][121]D.
Laboratory Evaluation
Standard laboratory workup includes serum creatinine, blood urea nitrogen (BUN), and uric acid [105]. However, conventional markers often lack the sensitivity required for early detection [116]D[120]D.
Standard and Emerging Biomarkers
- Uric Acid: Elevated serum uric acid (SUA) levels are associated with early impaired kidney function (EIKF) even in patients with newly diagnosed type 2 diabetes and otherwise normal SUA levels [26].
- Immune-Inflammatory Markers: Chronic inflammation is central to DKD pathogenesis. Meta-analyses have identified several diagnostic markers, including the red blood cell distribution width (RDW), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI), all of which are significantly elevated in patients with DKD [106].
- Monocyte-to-HDL Ratio (MHR): MHR serves as a composite biomarker integrating pro-inflammatory (monocytes) and anti-inflammatory (HDL) pathways, with higher ratios correlating with the presence of nephropathy [109].
- B-type Natriuretic Peptide (BNP): High-normal levels of BNP are associated with CKD progression independent of albuminuria, providing incremental prognostic value when added to standard UACR testing [85].
- Plasma R-spondin 2 (RSPO2): Circulating RSPO2 levels are associated with the severity of kidney injury and can help categorize patients into different risk groups [118]D.
- Urinary Metabolomics: Isoleucine has been identified as a specific prognostic biomarker for DKD progression, showing a strong correlation with renal histopathology [116]D.
The Eye-Kidney Axis
The retina and the kidney share similar microvascular structures, leading to parallel injury in the diabetic milieu [107]. The severity of (DR) is a critical diagnostic indicator. Patients with proliferative diabetic retinopathy (PDR) or the presence of hard exudates (HEs) on optical coherence tomography (OCT) have a significantly higher risk of renal function deterioration [111]. Serum and vitreous cytokines, such as those involved in angiogenic dysregulation, further link these two complications [107].
Risk Stratification and Adiposity
Effective requires identifying high-risk individuals before significant eGFR decline occurs.
- Clinical Risk Scores: The ELIXA trial risk score utilizes nine indicators—age, BMI, HbA1c, systolic blood pressure, HDL, triglycerides, smoking status, and the presence of retinopathy—to stratify patients into low, moderate, high, and very high-risk groups [16].
- Visceral Fat: Adiposity is a major driver of renal decline. The Metabolic Score for Visceral Fat (METS-VF) and directly measured visceral fat area (VFA) are predictive of incident DKD [19][29]D. High BMI variability, or "metabolic cycling," also predicts a higher risk of a ≥ 50% eGFR decline [34]D.
- Family History: A family history of is significantly associated with higher odds of developing DKD, suggesting a genetic predisposition to microvascular injury [33]D.
Differential Diagnosis: DKD vs. NDKD
Distinguishing DKD from non-diabetic kidney disease (NDKD) is vital, as management strategies may differ. NDKD should be suspected if the patient lacks retinopathy, has a rapid decline in eGFR, or presents with sudden-onset nephrotic syndrome [121]D. A non-invasive diagnostic nomogram incorporating duration of diabetes, presence of retinopathy, and other clinical variables can help discriminate between these entities without the need for a biopsy in many cases [121]D.
Diagnostic Algorithm
- Step 1: Annual Screening. Perform UACR and eGFR in all patients with type 2 diabetes at diagnosis and type 1 diabetes after 5 years of duration [29]D.
- Step 2: Confirmation. If UACR is ≥ 30 mg/g, repeat the test. Two of three samples over a 3-to-6-month period must be elevated to confirm persistent albuminuria [29]D.
- Step 3: Comprehensive Assessment. Evaluate for diabetic retinopathy via fundoscopic exam or OCT [111]. Assess inflammatory markers (e.g., SII, MHR) and BNP to refine the risk profile [106][109][85].
- Step 4: Risk Scoring. Apply the ELIXA or METS-VF scores to determine the intensity of monitoring required [16][29]D.
- Step 5: Renal Biopsy. Consider biopsy only if clinical features are atypical for DKD (e.g., absence of retinopathy, hematuria, or rapid eGFR loss) to rule out NDKD [121]D.
| Test | Finding in DKD | Clinical Significance | Timing |
|---|---|---|---|
| UACR | ≥ 30 mg/g | Primary marker of glomerular damage [29]D | Annual screening |
| eGFR | < 60 mL/min/1.73 m² | Defines stage of chronic kidney disease [29]D | Annual screening |
| Fundoscopy/OCT | Retinopathy / Hard Exudates | Strong surrogate for renal microvascular injury [111] | At diagnosis and annually |
| BNP | High-normal levels | Predicts eGFR decline independent of albuminuria [85] | Risk stratification |
| SII / MHR | Elevated | Reflects systemic micro-inflammation [106][109] | Supplemental workup |
| Urinary Isoleucine | Elevated | Prognostic marker for rapid progression [116]D | Emerging/Research |
Differential Diagnosis
- ▸Non-diabetic kidney disease (NDKD) occurs in up to 40% of diabetic patients with renal impairment, with IgA nephropathy and membranous nephropathy being the most common differentials [121][137].
- ▸The absence of diabetic retinopathy and the presence of hematuria are the strongest clinical predictors of NDKD rather than pure diabetic nephropathy [126].
- ▸Novel non-invasive biomarkers, such as urinary extracellular vesicle CKAP4 and specific miRNA profiles (e.g., miR-27b-3p), offer high sensitivity and specificity for differentiating DN from NDKD [143][146].
The differential diagnosis of diabetic nephropathy (DN), also referred to as (DKD), primarily involves distinguishing it from non-diabetic kidney disease (NDKD) or identifying the coexistence of both [126]. While DN is the most common cause of chronic kidney disease (CKD) globally, up to 40% of diabetic patients with renal dysfunction may have an underlying NDKD [121]D[129]. Accurate differentiation is critical because NDKD often requires distinct therapeutic interventions, such as immunosuppression, which are not indicated for pure DN [126][132]D.
Clinical Red Flags for NDKD
Clinicians should maintain a high index of suspicion for NDKD when the clinical presentation deviates from the typical natural history of DN. Key "red flags" include:
- Absence of : The presence of retinopathy has a high specificity for DN; its absence strongly suggests NDKD, particularly in Type 1 Diabetes [121]D[126].
- Rapid Decline in GFR: DN typically progresses slowly. A sudden drop in estimated glomerular filtration rate (eGFR) may indicate rapidly progressive glomerulonephritis (RPGN) or acute interstitial nephritis [139]C.
- Active Urinary Sediment: While DN can present with microscopic hematuria, the presence of dysmorphic red blood cells or red cell casts suggests a primary glomerulonephritis such as (IgAN) [121]D[137].
- Short Duration of Diabetes: Renal injury occurring within <5 years of the onset of Type 2 Diabetes (T2DM) is more likely to be NDKD [126].
- Heavy Proteinuria without Retinopathy: Nephrotic-range proteinuria in the absence of microvascular complications elsewhere should prompt a biopsy [147]D.
Primary Differentials and Co-occurrences
IgA Nephropathy (IgAN)
IgAN is the most frequent primary glomerular disease found in diabetic patients undergoing biopsy [137]. It often presents with hematuria and may progress to end-stage kidney disease (ESKD) at rates similar to DN [151]D. In Southeast Asia, IgAN remains a major contributor to advanced CKD alongside DN [129].
[[Membranous Nephropathy]] (MN)
MN is a common cause of nephrotic syndrome in elderly diabetic patients [147]D. It frequently coexists with DN (DN-MN). Patients with concurrent DN-MN often present with worse baseline renal function (median eGFR 68.2 mL/min/1.73 m²) compared to those with MN alone [142]D.
Obesity-Related Glomerulopathy (ORG)
ORG is an emerging differential characterized by glomerulomegaly and perihilar focal segmental glomerulosclerosis (FSGS) [131]D. It can affect up to 40% of individuals with excess adiposity, regardless of GFR, and may mimic the early hyperfiltration stages of DN [131]D.
Anti-Glomerular Basement Membrane (Anti-GBM) Disease
Though rare, anti-GBM disease can coexist with DN, presenting as a sudden clinical decline and reversible dialysis dependence if treated aggressively with plasma exchange and immunosuppression [139]C. Sero-negative cases have been reported where linear IgG deposition is only visible on biopsy [127]C.
Diagnostic Algorithm for Differentiation
- Step 1: Clinical Risk Assessment — Evaluate the duration of diabetes, HbA1c levels, and the presence of diabetic retinopathy. Use a clinical nomogram incorporating these variables to estimate the probability of DN vs. NDKD [121]D[126].
- Step 2: Urinary and Serological Screening — Order a urinalysis to check for hematuria and a comprehensive serological panel (ANA, ANCA, anti-GBM, C3/C4) if NDKD is suspected [132]D[139]C.
- Step 3: Advanced Biomarker Evaluation — Consider non-invasive biomarkers such as urinary extracellular vesicle (uEV) levels of CKAP4, which shows a sensitivity of 98.77% and specificity of 100% for DN [143]D. Plasma proteomic profiles (e.g., DAPA-CKD panel) can further distinguish DKD from other glomerulonephritides [124].
- Step 4: Renal Biopsy — Perform a kidney biopsy if red flags are present. This remains the gold standard for definitive diagnosis, especially when clinical features are atypical [135]D[137].
Laboratory and Imaging Differentials
| Test | Finding Suggestive of DN | Finding Suggestive of NDKD | Sensitivity/Specificity |
|---|---|---|---|
| Diabetic Retinopathy | Present in >90% of T1DM with DN | Often absent | High specificity for DN [126] |
| Hematuria | Rare or microscopic | Common (e.g., IgAN, GN) | High sensitivity for NDKD [121]D |
| uEV CKAP4 | Significantly elevated | Low/Normal | Sens 98.7%, Spec 100% [143]D |
| miR-27b-3p | Reduced expression | Variable | Associated with fibrosis [146]D |
| CEUS (Ultrasound) | Specific vascular resistance patterns | Normal or different resistance | High diagnostic accuracy [144]D |
Electrodiagnostic Studies
While not used to diagnose nephropathy itself, electrodiagnostic studies (NCS/EMG) are essential in the systemic evaluation of diabetic patients to differentiate uremic polyneuropathy from [138]C. In cases of suspected systemic amyloidosis (e.g., ALECT2), these studies help characterize the extent of neurological involvement [138]C.
| Feature | Diabetic Nephropathy (DN) | Non-Diabetic Kidney Disease (NDKD) |
|---|---|---|
| Diabetes Duration | Usually >5-10 years | Often <5 years [126] |
| Retinopathy | Highly correlated | Frequently absent [121]D |
| Proteinuria | Gradual onset | May be sudden/nephrotic [147]D |
| Hematuria | Uncommon/Microscopic | Common/Gross (in GN) [121]D |
| GFR Decline | Slow and steady | Can be rapid (RPGN) [139]C |
Supportive Care and Complication Management
- ▸The 'eye-kidney axis' dictates that diabetic retinopathy severity is a primary predictor of renal function deterioration and should guide monitoring frequency.
- ▸Nonsteroidal MRAs like finerenone (10-20 mg) provide superior cardiorenal protection with a lower risk of hyperkalemia compared to traditional steroidal MRAs.
- ▸Integrated endocrine-transplant care models significantly improve metabolic outcomes and graft survival in the first year following kidney transplantation.
The of (DKD) has evolved from simple glycemic control to a comprehensive cardiorenal-metabolic strategy. This approach addresses the "eye-kidney axis," systemic inflammation, and the high residual risk of cardiovascular events that persist despite standard renin-angiotensin-aldosterone system (RAAS) inhibition [107][61]D. Effective supportive care requires a multi-pronged protocol to mitigate microvascular damage and prepare for potential renal replacement therapy (RRT).
Step 1: Initial Assessment and Risk Stratification
Clinicians must first classify the patient's risk using the KDIGO risk categories, which integrate estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) [18]. A comprehensive assessment includes screening for comorbid microvascular complications, particularly (DR). The presence of proliferative DR or hard exudates on optical coherence tomography is a potent predictor of rapid renal function deterioration (eGFR decline >15% over 5 years) [111].
Utilize the ELIXA cardiorenal risk score to identify high-risk individuals. This score incorporates nine clinical indicators: age, BMI, HbA1c, systolic blood pressure (SBP), HDL cholesterol, triglycerides, smoking status, DR status, and UACR [16]. High HbA1c variability is an independent risk factor for DKD progression and should be stabilized to prevent fluctuating metabolic stress on the glomerular basement membrane [13].
Step 2: Hemodynamic and Metabolic Optimization
Aggressive management of blood pressure and glucose is foundational. For patients with T2D, blood pressure targets should be individualized by age; however, remains a primary modifiable driver of kidney failure across all cohorts [24].
Administer SGLT2 inhibitors (SGLT2i) (e.g., Dapagliflozin 10 mg daily) as first-line therapy for renoprotection [162]C. These agents reduce glucose reabsorption and intraglomerular pressure, though clinicians must monitor for rare complications like osmotic nephropathy, which can present as oliguric acute kidney injury (AKI) with serum creatinine elevations (e.g., from 2.0 to 8.3 mg/dL) [162]C. For patients with high atherosclerotic risk, dual therapy with an SGLT2i and a GLP-1 receptor agonist (GLP-1RA) (e.g., Lixisenatide 20 mcg SC daily or Semaglutide) is recommended to provide additive cardiorenal benefits [153][152]. GLP-1RAs are particularly effective at reducing albuminuria and slowing eGFR decline regardless of the patient's BMI [113]D[161].
Step 3: Mineralocorticoid Receptor Antagonism and Potassium Management
To address residual inflammatory and fibrotic risks, incorporate nonsteroidal mineralocorticoid receptor antagonists (MRAs).
Protocol for Finerenone Initiation:
- Check Baseline eGFR and Potassium: Ensure eGFR is ≥25 mL/min/1.73 m² and serum potassium is ≤4.8 mEq/L [84].
- Dosing: Start Finerenone 10 mg or 20 mg orally once daily [84][88].
- Monitoring: Recheck potassium at 4 weeks. Finerenone significantly reduces UACR and the risk of progression to kidney failure in both Type 1 and Type 2 diabetes [84][88]. Unlike steroidal MRAs (e.g., spironolactone), nonsteroidal MRAs like finerenone have a lower incidence of hyperkalemia and are more effective at improving KDIGO risk categories [156]D[18].
Step 4: Nutritional and Lifestyle Interventions
Lifestyle modifications should focus on improving the Oxidative Balance Score (OBS). A high OBS, derived from 20 dietary and lifestyle factors (e.g., high antioxidant intake, non-smoking), is associated with a significantly lower risk of microvascular complications [21]. Patients should adopt healthful dietary patterns, such as the DASH or Mediterranean diets, which have been shown to reduce the hazard ratio for DKD progression [45]. Clinicians should also monitor for lower-extremity arterial disease; patients with a history of lower-extremity amputation (LEA) often exhibit higher inflammatory markers and require closer renal monitoring due to the high correlation between LEA and eGFR decline [155].
Step 5: Preparation for Renal Replacement Therapy (RRT)
When eGFR approaches <15-20 mL/min/1.73 m², transition to RRT planning is essential.
- Kidney Transplantation: This is the preferred RRT modality. Outcomes are significantly improved when patients receive care through an endocrinology-integrated transplant clinic, which optimizes HbA1c and blood pressure during the critical first 12 months post-transplant [154].
- Dialysis Management: For patients on dialysis, Continuous Glucose Monitoring (CGM) is a reliable tool for glycemic assessment, overcoming the inaccuracies of HbA1c in end-stage kidney disease [115]D.
- Atypical Presentation: If a patient experiences rapidly progressive renal failure with hematuria, consider rare co-pathologies like anti-glomerular basement membrane (anti-GBM) disease, which requires urgent plasmapheresis and immunosuppression rather than standard DKD supportive care [139]C.
| Drug Class | Representative Agent | Dose/Route | Primary Benefit | Key Adverse Effect | Evidence Level |
|---|---|---|---|---|---|
| Nonsteroidal MRA | Finerenone | 10-20 mg PO daily | Reduced UACR & kidney failure risk [84][88] | Hyperkalemia (lower risk than steroidal) | 1b |
| SGLT2 Inhibitor | Dapagliflozin | 10 mg PO daily | Hemodynamic renoprotection [162]C | Osmotic nephropathy, AKI | 1b |
| GLP-1 RA | Lixisenatide | 20 mcg SC daily | Reduced arterial stiffness & albuminuria [152] | Gastrointestinal distress | 1b |
| Antioxidant | Resveratrol | Experimental | Reduced I/R injury & oxidative stress [67]D | N/A (Pre-clinical) | 5 |
Prognosis and Long-term Outcomes
- ▸Cardiovascular death is a major competing risk, often occurring before patients reach end-stage renal disease.
- ▸Glycemic and BMI variability are independent predictors of rapid eGFR decline, regardless of mean HbA1c levels.
- ▸Finerenone and SGLT2 inhibitors significantly improve the long-term renal prognosis by reducing albuminuria and slowing eGFR slope decline.
The prognosis of (DN) is characterized by a progressive decline in renal function and a high burden of cardiovascular morbidity. Patients face a significant "competing risk" where the likelihood of death from cardiovascular causes often exceeds the probability of reaching (ESKD) [117]D. Long-term survival is heavily influenced by the of metabolic variability, blood pressure, and the implementation of neurohormonal blockade. In specialized cohorts, such as those on peritoneal dialysis, mortality can reach 51.3% over a median follow-up of 40 months, with cardiovascular events accounting for nearly half of these deaths [117]D.
Validated Prognostic Scores and Risk Stratification
Early identification of high-risk individuals is essential for targeted intervention. Several scoring systems have been developed to predict renal decline and cardiovascular events:
- ELIXA Risk Score: This multivariable tool utilizes nine clinical indicators: age, BMI, HbA1c, systolic blood pressure, HDL cholesterol, triglycerides, smoking status, , and UACR [16]. It effectively stratifies patients into low, moderate, high, and very high-risk groups for cardiorenal outcomes [16].
- Non-invasive Nomogram: For patients with renal insufficiency, a five-variable model (incorporating diabetic retinopathy and other clinical markers) helps differentiate between pure DN and non- (NDKD), which carries a different prognostic trajectory [121]D.
- Machine Learning Models: In acute settings, such as the ICU, machine learning algorithms using variables like age and serum creatinine are used to predict in-hospital mortality for DN patients [169]D.
Metabolic and Clinical Prognostic Factors
Beyond static measurements of HbA1c, dynamic metabolic markers have emerged as critical predictors of progression. Glycemic variability (GV), measured by the coefficient of variation, is strongly associated with renal events; patients in the highest quartile of GV experience a 43.6% incidence of renal events compared to only 12.8% in the lowest quartile [27]. Similarly, BMI variability serves as an index of "metabolic cycling" and independently predicts a ≥50% decline in eGFR in patients with type 1 diabetes [34]D.
| Factor | Good Prognosis | Poor Prognosis |
|---|---|---|
| Glycemic Control | Stable HbA1c levels | High Glycemic Variability [27] |
| Biomarkers | BNP < 14.5 pg/mL | BNP > 14.5 pg/mL [85] |
| Nutritional Status | High Prognostic Nutritional Index (PNI) | Low PNI + High HbA1c [166] |
| Weight Stability | Consistent BMI | High BMI Variability [34]D |
| Lipid/Glucose Index | Low TyG Index | High Triglyceride-Glucose (TyG) Index [44] |
Biomarkers of Progression
Novel biomarkers provide incremental prognostic value over traditional albuminuria and eGFR measurements:
- B-type Natriuretic Peptide (BNP): High-normal levels of BNP (>14.5 pg/mL) are associated with a ≥30% eGFR decline, independent of baseline albuminuria [85].
- R-spondin 2 (RSPO2): Plasma RSPO2 levels correlate with the severity of kidney injury and can predict the risk of DKD progression [118]D.
- Urinary Isoleucine: Metabolomic profiling has identified urinary isoleucine as a specific prognostic biomarker for the progression of biopsy-confirmed DN [116]D.
- Short-Chain Fatty Acids (SCFAs): Trajectories of serum SCFAs are linked to adverse kidney outcomes, including the doubling of serum creatinine [165].
Long-term Sequelae and Quality of Life
Chronic kidney disease in diabetes leads to multi-system complications that impact quality of life (QoL). Patients often suffer from impaired nutritional status and systemic inflammation (elevated CRP, TNF-α, and IL-6) [168]. Structured nutritional interventions, such as the combined with SGLT2 inhibitors like dapagliflozin 10 mg/day, have been shown to improve SF-36 quality of life scores and renal parameters [168]. In the post-transplant setting, integrated endocrinology care is vital, as 80% of patients may achieve better metabolic control when managed in specialized endocrine-transplant clinics [154].
Protocol for Long-term Risk Management
To optimize the long-term prognosis, clinicians should follow a structured risk-mitigation protocol:
- Step 1: Baseline Stratification: Calculate the ELIXA risk score [16] and assess for diabetic retinopathy, which strongly correlates with renal prognosis [121]D.
- Step 2: Therapeutic Optimization: Initiate SGLT2 inhibitors (e.g., dapagliflozin or empagliflozin) to reduce the risk of eGFR decline [14]. In patients with persistent albuminuria despite ACE inhibitor/ARB therapy, add finerenone 10-20 mg/day to delay progression to ESKD [84][93].
- Step 3: Monitoring Variability: Move beyond HbA1c to monitor glycemic variability [27] and BMI fluctuations [34]D.
- Step 4: Nutritional Support: Implement adjunctive nutritional interventions (e.g., Luteolin supplementation or Mediterranean diet) to reduce inflammation and improve QoL [167][168].
Landmark Trials and Key Evidence
- ▸SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) are now foundational therapy for DN, reducing ESKD risk even in patients with eGFR as low as 20-25 mL/min/1.73 m².
- ▸Finerenone (ns-MRA) provides significant cardio-renal protection across all stages of CKD, including Stage 4, and improves KDIGO risk categorization.
- ▸The FLOW trial established semaglutide 1 mg as a potent agent for reducing kidney failure, cardiovascular events, and all-cause mortality in diabetic kidney disease.
The of (DN) has undergone a paradigm shift from simple glycemic and blood pressure control to a multi-pronged approach utilizing organ-protective therapies. This evolution is rooted in several landmark clinical trials that transitioned the standard of care from renin-angiotensin system (RAS) blockade to the foundational use of sodium-glucose cotransporter 2 (SGLT2) inhibitors, non-steroidal mineralocorticoid receptor antagonists (ns-MRAs), and glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
The Foundation: RAAS Blockade
The early evidence for kidney protection in type 2 diabetes (T2D) was established by the RENAAL and IDNT trials, which demonstrated that angiotensin receptor blockers (ARBs), specifically losartan and irbesartan, significantly reduced the risk of doubling serum creatinine or reaching end-stage kidney disease (ESKD) [176]. Recent post hoc analyses of these trials confirm that the efficacy of ARBs is consistent across both sexes, with no significant sex-treatment interaction for kidney or cardiovascular outcomes [176]. Despite these benefits, a significant residual risk remained, necessitating the development of newer therapeutic classes.
The SGLT2 Inhibitor Revolution
SGLT2 inhibitors have redefined the treatment of DN by providing hemodynamic and metabolic benefits that slow the decline of the estimated glomerular filtration rate (eGFR).
CREDENCE
The CREDENCE trial was a pivotal study specifically designed to evaluate kidney outcomes in patients with T2D and albuminuric chronic kidney disease (CKD). Using canagliflozin 100 mg daily, the trial demonstrated a significant reduction in the primary composite outcome of ESKD, doubling of serum creatinine, or renal/cardiovascular death [170][178].
- Clinical Impact: The benefits were consistent across geographic regions, racial groups, and age categories, including older adults (≥75 years) [174][178][187].
- Metabolic Effects: Canagliflozin also reduced the need for insulin initiation or dose intensification by >25%, potentially mitigating the weight gain and hypoglycemia risks associated with insulin [173].
- Biomarkers: Analysis of CREDENCE data revealed that higher baseline levels of lactate and free fatty acids were associated with a lower risk of CKD progression [175]. Furthermore, the insulin-like growth factor (IGF) axis and vascular endothelial growth factors (VEGF) have emerged as potential predictors of cardio-renal risk, with higher sFLT-1 and lower PlGF levels correlating with worse outcomes [180][184].
DAPA-CKD and EMPA-KIDNEY
The DAPA-CKD trial extended these findings to patients with and without T2D, showing that dapagliflozin 10 mg significantly slowed CKD progression and reduced the risk of kidney failure [179][192]. Proteomic analyses from this trial identified specific molecular pathways, such as those involving TNFR-1 and KIM-1, that differentiate from other etiologies like glomerulonephritis [124].
The EMPA-KIDNEY trial further broadened the evidence base by including patients with eGFR as low as 20 mL/min/1.73 m² and those with lower levels of albuminuria [181][190]. This trial confirmed that empagliflozin 10 mg reduces the risk of kidney disease progression or cardiovascular death across a wide spectrum of CKD [181].
Non-steroidal Mineralocorticoid Receptor Antagonists
Finerenone, a selective non-steroidal MRA, was developed to provide the anti-inflammatory and anti-fibrotic benefits of mineralocorticoid receptor blockade with a lower risk of hyperkalemia compared to steroidal MRAs.
FIDELIO-DKD and FIGARO-DKD (FIDELITY)
The FIDELITY analysis, a pooled dataset of the FIDELIO-DKD and FIGARO-DKD trials (N=13,026), demonstrated that finerenone (10 or 20 mg) significantly reduced the risk of cardiovascular events and kidney failure [88][186].
- Stage 4 CKD: Finerenone remained effective and safe in patients with Stage 4 CKD (eGFR <30 mL/min/1.73 m²), a population with limited treatment options [186].
- Asian Population: Subanalyses showed that finerenone significantly reduced the chronic eGFR slope decline in Asian patients, with a mean between-group difference of 1.08 mL/min/1.73 m² per year compared to placebo [92][183].
- KDIGO Risk: Finerenone therapy increased the likelihood of improving a patient's KDIGO risk category (OR 1.47 at 36 months), which strongly correlates with reduced cardiovascular risk [18].
GLP-1 Receptor Agonists: The FLOW Trial
The FLOW trial is the first dedicated kidney outcomes trial for a GLP-1 RA. It randomized participants to semaglutide 1 mg weekly or placebo.
- Primary Outcome: Semaglutide significantly reduced major kidney events, cardiovascular outcomes, and all-cause mortality [177].
- Infection Risk: Interestingly, semaglutide also reduced the risk of serious infections and -related adverse events, suggesting broader systemic benefits in this high-risk population [195]D.
Risk Stratification and Future Directions
Modern management increasingly relies on multivariable risk prediction. The KidneyIntelX.dkd score, which combines biomarkers (TNFR-1, TNFR-2, KIM-1) with clinical data, has shown superior prognostic utility compared to standard KDIGO risk classification in the CANVAS and CREDENCE cohorts [170]. Machine learning models incorporating age, BMI, NT-proBNP, and troponin T are also being validated to predict cardio-kidney risk [171].
Ongoing research, such as the FIONA trial, is investigating the use of finerenone in pediatric populations with CKD and proteinuria to determine if the benefits seen in adults can be extrapolated to children [191].
| Trial | Year | N | Intervention | Key Finding |
|---|---|---|---|---|
| RENAAL | 2001 | 1,513 | Losartan 50-100 mg | Established ARBs as standard of care for kidney protection [176]. |
| CREDENCE | 2019 | 4,401 | Canagliflozin 100 mg | 30% reduction in composite of ESKD, doubling of SCr, or renal/CV death [170][178]. |
| DAPA-CKD | 2020 | 4,304 | Dapagliflozin 10 mg | Reduced CKD progression in patients with and without T2D [179]. |
| FIDELITY | 2021 | 13,026 | Finerenone 10/20 mg | Pooled analysis showing significant reduction in CV and kidney outcomes [186]. |
| EMPA-KIDNEY | 2023 | 6,609 | Empagliflozin 10 mg | Demonstrated benefits in patients with eGFR down to 20 mL/min/1.73 m² [181]. |
| FLOW | 2024 | 3,533 | Semaglutide 1 mg | First GLP-1 RA trial to show primary kidney and mortality benefits [177]. |
Special Populations
- ▸Finerenone (10-20 mg) is an emerging therapeutic option for albuminuric DKD in Type 1 Diabetes patients already on RAS inhibitors [84].
- ▸Incremental peritoneal dialysis (iPD) is superior to full-dose PD for preserving residual renal function in elderly ESKD patients with baseline RRF ≥3 mL/min/1.73 m² [117].
- ▸Integrated endocrine-transplant care models significantly improve metabolic outcomes and HbA1c stability in diabetic kidney transplant recipients [154].
of (DKD) requires nuanced adjustments based on age, diabetes type, and comorbid status. While standard therapies like and form the backbone of treatment, specific populations such as pediatric patients with type 1 diabetes (T1DM), the elderly, and kidney transplant recipients require tailored risk stratification and therapeutic protocols [16][84][154].
Pediatrics and Type 1 Diabetes (T1DM)
In pediatric and young adult populations with T1DM, DKD remains a primary driver of long-term morbidity. Unlike type 2 diabetes (T2DM), where DKD may be present at diagnosis, T1DM-associated nephropathy typically follows a duration-dependent course. Recent evidence has expanded the use of nonsteroidal mineralocorticoid receptor antagonists (MRAs) to this group. Finerenone (10 mg or 20 mg daily) has been evaluated in adults with T1DM and CKD (eGFR 25 to <90 mL/min/1.73 m² and UACR 200 to <5000 mg/g), demonstrating a potential role in reducing albuminuria when added to maximum tolerated RAS inhibition [84]. Genetic screening using whole-exome sequencing (WES) is increasingly utilized to identify novel genomic variants that predispose T1DM patients to accelerated renal decline, facilitating personalized risk assessment [196]D.
Protocol: Management of DKD in T1DM
- Screening: Initiate annual UACR and eGFR screening 5 years after T1DM diagnosis or at age 11.
- RAS Inhibition: Titrate ACE inhibitors or ARBs to the maximum tolerated dose if UACR >30 mg/g.
- MRA Addition: Consider Finerenone 10–20 mg daily for persistent albuminuria (UACR >200 mg/g) despite RAS inhibition, provided serum potassium is <4.8 mmol/L [84].
- Novel Therapies: In refractory cases (Stage II-IV), mesenchymal stem cell (MSC) infusions are under investigation to stabilize GFR decline [112].
The Elderly and Advanced Age
Elderly patients (typically defined as >65 years) present a complex challenge due to the high prevalence of cardiovascular comorbidities and the risk of hyperkalemia. Risk stratification in this group should utilize the ELIXA score, which incorporates nine clinical indicators: age, BMI, HbA1c, systolic blood pressure, HDL, triglycerides, smoking status, and presence of [16]. In the elderly, visceral adiposity—measured via the Body Roundness Index (BRI) or Metabolic Score for Visceral Fat (METS-VF)—is a stronger predictor of DKD and left ventricular diastolic dysfunction than BMI alone [36]D[29]D.
For elderly patients reaching end-stage kidney disease (ESKD), incremental peritoneal dialysis (iPD) is a viable strategy. In patients with residual renal function (RRF) ≥3 mL/min/1.73 m², iPD (starting with fewer exchanges) has been shown to preserve RRF longer than full-dose PD, with a significantly lower risk of RRF loss (HR 0.385) [117]D.
Pregnancy and Sex-Specific Considerations
Sex-specific differences in visceral fat distribution significantly impact DKD risk. Prospective cohort data indicate that the association between visceral fat area (VFA) and incident DKD is more pronounced in women than in men, particularly in those with a lower BMI [19]. While specific trial data for newer agents like finerenone or lixisenatide in pregnancy are limited, the focus remains on strict blood pressure control and metabolic management. High-normal levels of B-type natriuretic peptide (BNP) serve as an independent prognostic marker for CKD progression in this group, even when albuminuria is not yet severe [85].
Kidney Transplant Recipients
Patients with pre-existing diabetes who undergo kidney transplantation face unique metabolic challenges, including post-transplant hyperglycemia and the nephrotoxic effects of immunosuppressants. The Endocrine Transplant Clinic (ETC) model—an integrated care approach where endocrinologists and transplant surgeons co-manage patients—has demonstrated superior outcomes compared to standard care [154].
| Outcome | ETC Model (Integrated) | Standard Transplant Care |
|---|---|---|
| HbA1c Control | Significant reduction at 12 months | Minimal change/Fluctuating |
| BMI Management | Stable or reduced | Frequent post-transplant weight gain |
| BP Control | Targeted titration | Variable |
Ethnic Disparities and East Asian Populations
East Asian populations exhibit distinct genetic and environmental risk factors for DKD. Multi-omics analyses in these cohorts have identified specific microbiota-metabolite interactions, such as urinary isoleucine, as sensitive prognostic biomarkers for early DKD detection where traditional markers like UACR may fail [116]D[120]D. Furthermore, the severity of and the presence of hard exudates on optical coherence tomography (OCT) are more strongly associated with a >15% eGFR decline over 5 years in these populations [111].
| Risk Indicator | Clinical Threshold/Detail |
|---|---|
| Age | Increasing age correlates with higher cardiorenal risk |
| BMI | Elevated BMI increases risk; BRI/METS-VF are more precise [36]D[29]D |
| HbA1c | Poor glycemic control is a primary driver |
| Systolic BP | Target <130 mmHg for high-risk groups |
| Lipids | Low HDL and high Triglycerides are independent predictors |
| Retinopathy | Presence of PDR increases risk of renal deterioration [111] |
Guidelines and Resources
- ▸Management has shifted to a 'five-pillar' approach: RASi, SGLT2i, GLP-1 RA, ns-MRA (finerenone), and intensive metabolic control [198][205].
- ▸Screening must occur annually using both eGFR and UACR, as these parameters often decline discordantly [209][214].
- ▸Intensive blood pressure control (<130/80 mmHg) and lipid management (LDL <1.4 mmol/L) are essential to mitigate the high cardiovascular risk associated with DKD [199][207].
The of (DKD) has undergone a paradigm shift from simple glycemic and blood pressure control to a comprehensive, multi-pillar pharmacological approach designed to provide maximal nephroprotection and cardioprotection [198][205]. Current international and national guidelines, including those from KDIGO (Kidney Disease: Improving Global Outcomes) and the American Diabetes Association (ADA), emphasize the early identification of risk and the rapid implementation of guideline-directed medical therapy (GDMT) to prevent progression to end-stage kidney disease (ESKD) and reduce the high burden of cardiovascular mortality [213][214]D.
The Five Pillars of Nephroprotection
Recent position statements, such as those from the Polish Society of Nephrology (2024) and the Macedonian Society of Nephrology (2024), have consolidated management into five essential pillars [198][205]. This structured approach is designed to address the hemodynamic, metabolic, and inflammatory pathways that drive DKD progression.
- RAS Inhibition: The use of an ACE inhibitor (ACEi) or Angiotensin II Receptor Blocker (ARB) remains the foundational therapy. These agents reduce intraglomerular pressure by inducing efferent arteriolar vasodilation [198].
- SGLT2 Inhibitors: Sodium-glucose cotransporter 2 inhibitors (e.g., Dapagliflozin 10 mg/day or Canagliflozin 100 mg/day) are now recommended for nearly all patients with T2D and an eGFR ≥20–25 mL/min/1.73 m² [204][213]. They provide nephroprotection through the restoration of tubuloglomerular feedback and reduction of proximal tubular workload [198].
- GLP-1 Receptor Agonists: Agents like Semaglutide 1 mg/week (subcutaneous) are prioritized for patients with persistent albuminuria or high cardiovascular risk, as demonstrated in the FLOW trial [177][198].
- Non-steroidal Mineralocorticoid Receptor Antagonists (ns-MRA): Finerenone (10 mg or 20 mg/day) is indicated for patients with T2D and CKD who have persistent albuminuria despite optimized RASi and SGLT2i therapy [18][211]. Unlike steroidal MRAs, finerenone has a higher affinity for the receptor and a lower risk of hyperkalemia, providing potent anti-inflammatory and anti-fibrotic effects [198].
- Metabolic and Blood Pressure Control: Intensive management of hyperglycemia and (targeting <130/80 mmHg in most guidelines) is critical [199][207].
Screening and Risk Stratification
Guidelines emphasize annual screening for all patients with type 2 diabetes and those with type 1 diabetes for ≥5 years [214]D. Screening must include both estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR), as either can decline independently [209].
Protocol: Implementation of Guideline-Directed Medical Therapy (GDMT)
- Step 1: Initial Assessment. Measure eGFR and UACR. If UACR is >30 mg/g or eGFR is <60 mL/min/1.73 m², initiate nephroprotective therapy [203][214]D.
- Step 2: Foundational Therapy. Start the maximum tolerated dose of an ACEi or ARB. Add an SGLT2 inhibitor if eGFR is above the local regulatory threshold (typically 20–25 mL/min/1.73 m²) [198][213].
- Step 3: Optimization. If UACR remains >30 mg/g, add Finerenone 10–20 mg/day, monitoring serum potassium closely [18][211].
- Step 4: Cardiovascular Risk Reduction. If the patient has high cardiovascular risk or requires further glucose lowering, initiate a GLP-1 RA (e.g., Semaglutide) [177][199].
- Step 5: Adjunctive Therapy. Consider Pentoxifylline 400 mg TID in patients with advanced CKD (Stages III-IV) to further reduce albuminuria and provide cardioprotection [87]. In patients with metabolic acidosis (bicarbonate <22 mmol/L), initiate sodium bicarbonate to slow GFR decline [198].
Lipid and Blood Pressure Targets
Intensive lipid lowering is a cornerstone of DKD management due to the extreme cardiovascular risk in this population [200]. The ABCD-UKKA 2024 guidelines recommend a tiered approach to lipid management, emphasizing that CKD itself is an independent cardiovascular risk factor [199].
| Parameter | Target/Recommendation | Rationale |
|---|---|---|
| Blood Pressure | <130/80 mmHg (standard); <120 mmHg (intensive) | Intensive control (<120 mmHg) may further reduce major adverse kidney events, though requires close monitoring for AKI [207]. |
| Lipids (LDL-C) | <1.4 mmol/L (55 mg/dL) or >50% reduction | High-intensity (e.g., Atorvastatin 40 mg) are preferred to reduce the risk of MI and stroke [199][200]. |
| Glycemic Control | HbA1c 6.5%–8.0% (individualized) | Lower targets (6.5%–7.0%) for early CKD; higher targets for those at risk of hypoglycemia or with limited life expectancy [214]D. |
| Potassium | <5.0 mmol/L | Essential for the safe continuation of RASi and Finerenone; use potassium binders if necessary [221]D. |
Emerging Tools and Future Directions
Traditional risk markers (eGFR and UACR) are increasingly supplemented by novel biomarkers and artificial intelligence. The KidneyIntelX.dkd score, which combines biomarkers like TNFR-1, TNFR-2, and KIM-1 with clinical data, has shown superior prognostic utility in predicting GFR decline compared to KDIGO staging alone [170]. Economic analyses suggest that AI-driven risk stratification is cost-effective by allowing for the early allocation of intensive resources to high-risk patients [28]D. Furthermore, continuous glucose monitoring (CGM) is now recommended for patients on dialysis due to the inaccuracies of HbA1c in end-stage disease [212].
| Organization | Year | Key Recommendations |
|---|---|---|
| ADA (Standards of Care) | 2026 | Annual screening of UACR/eGFR; SGLT2i as first-line for eGFR ≥20; GLP-1 RA for CV risk [214]D. |
| KDIGO | 2024 | Comprehensive care including SGLT2i, RASi, and Finerenone; individualized HbA1c targets [213][217]D. |
| ABCD-UKKA (UK) | 2024/25 | Tiered approach to management; intensive lipid lowering (statin + ezetimibe) for all DKD patients [199][200]. |
| Spanish Society (SEN) | 2025 | Adoption of 'diabetic kidney disease' terminology; focus on early detection and multidisciplinary care [203]. |
| Saudi Clinical Guidelines | 2025 | Evidence-based national standards using GRADE methodology for SGLT2i and MRA use [202]. |
| Polish Society of Nephrology | 2024 | Defined the 'five pillars' of pharmacological nephroprotection [198]. |
References
- [1]
Heerspink HJL, List J, Perkovic V. “New clinical trial designs for establishing drug efficacy and safety in a precision medicine era.” Diabetes, obesity & metabolism (2018). PMID: 30294954 ↗
L2bTRIAL_NONRANDOMCited in: Definition, Synonyms, and Classification - [2]
Bansal A, Chonchol M. “Metabolic dysfunction-associated kidney disease: pathogenesis and clinical manifestations.” Kidney international (2025). PMID: 40379048 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [3]
Eckardt KU, Coresh J, Devuyst O et al.. “Evolving importance of kidney disease: from subspecialty to global health burden.” Lancet (London, England) (2013). PMID: 23727165 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [4]
Pozzilli P, Messina MV, Roden M. “Metabolic Cardiovascular Renal Disease (Met-CVRD): A New Nomenclature.” Diabetes/metabolism research and reviews (2025). PMID: 40888594 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [5]
Gao X, Wei J, Hao T et al.. “Dysgonomonas mossii Strain Shenzhen WH 0221, a New Member of the Genus Dysgonomonas Isolated from the Blood of a Patient with Diabetic Nephropathy, Exhibits Multiple Antibiotic Resistance.” Microbiology spectrum (2022). PMID: 35913210 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [6]
Kanasaki K, Ueki K, Nangaku M. “Diabetic kidney disease: the kidney disease relevant to individuals with diabetes.” Clinical and experimental nephrology (2024). PMID: 39031296 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [7]
Kalra PA. “Renal specific secondary hypertension.” Journal of renal care (2007). PMID: 17695554 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [8]
Tuncer O, Köster I, Meyer I et al.. “[Development and internal validation of case definitions for kidney disease in patients with diabetes based on routine data of statutory health insurance].” Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) (2025). PMID: 40451195 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [9]
Icks A, Rathmann W, Haastert B et al.. “[Quality of care and extent of complications in a population-based sample of patients with type 2 diabetes mellitus. The KORA Survey 2000].” Deutsche medizinische Wochenschrift (1946) (2006). PMID: 16418944 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [10]
Basu M, Ghosh S. “Chronic Kidney Disease with Risk Factor Diabetes: Need for Change in Nomenclature Reflecting Heterogeneity of Kidney Disease in Diabetes.” The Journal of the Association of Physicians of India (2026). PMID: 41818088 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [11]
Ding L, Li Z, Xia Y et al.. “Exosomes in diabetic kidney disease: pathogenesis, biomarker discovery, and emerging therapeutics-a comprehensive systematic review.” Renal failure (2026). PMID: 41845912 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [12]
Guo S, Zhao X. “Lipoprotein-associated phospholipase A2 and complications of diabetes mellitus: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 41767386 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Supportive Care and Complication Management - [13]
Wu C, Qin H, Wei M et al.. “Association between glycated hemoglobin variability and risk of diabetic kidney disease and diabetic retinopathy in diabetic patients: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 41694560 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Supportive Care and Complication Management - [14]
Guo Y, Gao W, Li S et al.. “Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in the treatment of diabetic kidney disease: a meta-analysis.” Frontiers in endocrinology (2025). PMID: 41675637 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes - [15]
Zhao J, Zhao L. “A meta-analysis of serum uric acid and diabetic nephropathy risk in type 2 diabetes.” Frontiers in endocrinology (2025). PMID: 41669246 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors - [16]
Jiang W, Wang J, Li J et al.. “Cardiorenal risk stratification in high-risk type 2 diabetes using a simple clinical score: findings from the ELIXA trial.” Frontiers in endocrinology (2026). PMID: 41928879 ↗
L1bRCTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Clinical Features and Variants, Diagnosis and Workup, Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations - [17]
Yang Y, Tan H, Xiao Z et al.. “Landscape of diabetic kidney disease drug clinical trials in China (2013-2023): global implications for innovation and policy.” Renal failure (2026). PMID: 41724716 ↗
L2bTRIAL_NONRANDOMCited in: Epidemiology and Risk Factors - [18]
Weingold R, Filippatos G, Anker SD et al.. “Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITY.” Journal of diabetes and its complications (2026). PMID: 41679125 ↗
L1bRCTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Clinical Features and Variants, Supportive Care and Complication Management, Landmark Trials and Key Evidence, Special Populations, Guidelines and Resources - [19]
Shi J, Zhao D, Wang J et al.. “Sex-specific and BMI-specific associations between visceral fat and diabetic kidney disease in patients with diabetes: a large-scale multicentre prospective cohort study.” The lancet. Diabetes & endocrinology (2026). PMID: 41991218 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Diagnosis and Workup, Special Populations - [20]
Yang R, Liu Y, Li J. “Assessing the association of FIB-4 index with diabetic kidney disease in patients with diabetes mellitus: a cross-sectional and retrospective study utilizing NHANES and clinical data.” Frontiers in endocrinology (2026). PMID: 41907551 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Special Populations - [21]
Hu J, Ge T, Zhu Q et al.. “Association between the oxidative balance score and risk of microvascular complications in type 2 diabetes: A prospective UK biobank cohort study.” Diabetes, obesity & metabolism (2026). PMID: 41705623 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Pathophysiology, Supportive Care and Complication Management, Special Populations - [22]
Deng L, Li X, Ran J et al.. “Acute-to-chronic glycemic ratio: a promising biomarker for prognosis of diabetic foot ulcers in a multi-center cohort study.” Diabetology & metabolic syndrome (2026). PMID: 41680933 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [23]
Deng Z, Yang J, Zhou H. “Development and validation of a model that predicts the risk of diabetic kidney disease in type 2 diabetes mellitus patients: a retrospective study.” Frontiers in endocrinology (2025). PMID: 41607464 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors - [24]
Chow EWK, Fan Y, Wu H et al.. “Age-specific associations between blood pressure and cardiovascular disease, kidney disease, and death among individuals with type 2 diabetes: a population-based cohort study.” Cardiovascular diabetology (2026). PMID: 41606584 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [25]
Sun T, Li S, Liu J. “Association between the total bilirubin to prothrombin time ratio index and diabetic retinopathy, nephropathy, peripheral neuropathy, and foot disease: a retrospective study and risk prediction model construction.” Frontiers in endocrinology (2025). PMID: 41601923 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [26]
Li X, Zhang X. “Association between serum uric acid and urinary uric acid excretion indicators and early impaired kidney function in newly diagnosed T2DM patients with normal serum uric acid levels: a retrospective study.” PeerJ (2026). PMID: 41777687 ↗
L2bTRIAL_NONRANDOMCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Diagnosis and Workup, Special Populations - [27]
Yang L, Zhou B, Deng R. “Relationship between glycemic variability and renal function progression in patients with diabetic nephropathy: A retrospective cohort study.” Medicine (2026). PMID: 41630253 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes - [28]
Sarker J, Abdelaziz AI, Crook J et al.. “Cost-Effectiveness Analysis of Artificial Intelligence-Driven Risk Stratification in Patients With Diabetic Kidney Disease in the US Veterans Population.” Kidney medicine (2026). PMID: 41993683 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Guidelines and Resources - [29]
Xu M, Yan H, Gu T et al.. “Visceral fat score predicts diabetic kidney disease: analysis of 20 years of U.S. NHANES data.” Renal failure (2026). PMID: 41947490 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Clinical Features and Variants, Diagnosis and Workup, Special Populations - [30]
Hirakawa Y, Sugawara Y, Nangaku M. “Prevalence of diagnostic Mendelian kidney disease variants in type 2 diabetes with and without diabetic kidney disease.” Journal of diabetes investigation (2026). PMID: 41923384 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [31]
Groothof D, Shehab NBN, Post A et al.. “SGLT2 Inhibitors, Muscle Loss, and Creatinine-Based Estimated GFR: An Integrative Conceptual Review of Renoprotection.” Kidney medicine (2026). PMID: 41908618 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [32]
Pantis C, Vesa CM, Ghitea TC et al.. “Diabetes Duration Is Associated with Declining Kidney Function: eGFR and CKD Burden Across Duration.” Journal of clinical medicine (2026). PMID: 41899160 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [33]
Xing Y, Yang X, Zhao Q. “The association between family history of hypertension and diabetic kidney disease in patients with diabetes: a cross-sectional study.” Frontiers in endocrinology (2026). PMID: 41877930 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Diagnosis and Workup, Special Populations - [34]
Ozdede M, Pavlou P, Avataneo M et al.. “Impact of Body Mass Index Variability on Kidney Disease Progression in a Large Type 1 Diabetes Cohort.” Diabetes/metabolism research and reviews (2026). PMID: 41854625 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Diagnosis and Workup, Prognosis and Long-term Outcomes - [35]
Lohia S, Zoidakis J, Vlahou A et al.. “Integrative Analysis on the Urinary Proteome of Diabetic Kidney Disease, with an Emphasis on Extracellular Matrix Proteins.” International journal of molecular sciences (2026). PMID: 41828502 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [36]
Li Y, Wang Z, Ma Y et al.. “The nonlinear association between Body Roundness Index and left ventricular diastolic dysfunction in type 2 diabetes.” Frontiers in endocrinology (2026). PMID: 41821734 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Special Populations - [37]
Nobayashi H, Satoh M, Hirose T et al.. “Comparison of SGLT2 Inhibitors for New-Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function.” Diabetes, obesity & metabolism (2026). PMID: 41804189 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors - [38]
Cobuz C, Ungureanu-Iuga M, Cobuz M. “An integrative analysis of cardiac autonomic neuropathy and nephropathy risk assessed with SUDOSCAN in individuals with type 2 diabetes.” Frontiers in endocrinology (2026). PMID: 41767395 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors - [39]
Lim MY, Lian W, Phua HP et al.. “Visit-to-visit HbA1c variability, risk of all-cause mortality and diabetes-related vascular complications among adult individuals with type 2 diabetes mellitus.” Diabetes, obesity & metabolism (2026). PMID: 41749305 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors - [40]
Yang Y, Liu Z, Huang Y et al.. “Associations of time in tight range, time in range, and glycated hemoglobin with albuminuria and diabetic kidney disease in adult type 2 diabetes: a cross-sectional study.” BMC endocrine disorders (2026). PMID: 41749212 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Clinical Features and Variants - [41]
Zhang J, Li Y, Dai B et al.. “The bidirectional association between obstructive sleep apnea and diabetic kidney disease: systematic review and meta-analysis.” Frontiers in endocrinology (2025). PMID: 41367908 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors - [42]
Li N, Sun J, Li H et al.. “Drug-gene interactions and the risk of diabetic microvascular complications: A population-based cohort study.” Diabetes, obesity & metabolism (2026). PMID: 41582657 ↗
L2bCOHORTCited in: Etiology and Triggering Factors, Supportive Care and Complication Management - [43]
Brillinger J, Filliter C, Salmasi S et al.. “Long-acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population-based cohort study.” Diabetes, obesity & metabolism (2026). PMID: 41521903 ↗
L2bCOHORTCited in: Etiology and Triggering Factors, Prognosis and Long-term Outcomes - [44]
Oh R, Kim S, Cho SH et al.. “Elevated triglyceride-glucose index is associated with increased risk of chronic kidney disease and end-stage renal disease in type 1 diabetes: Nationwide cohort study.” Diabetes, obesity & metabolism (2026). PMID: 41500979 ↗
L2bCOHORTCited in: Etiology and Triggering Factors, Prognosis and Long-term Outcomes - [45]
Li R, Xu K, Zhu K et al.. “Healthful dietary patterns and risks of microvascular complications among individuals with type 2 diabetes: a prospective cohort study.” The American journal of clinical nutrition (2026). PMID: 41298211 ↗
L2bCOHORTCited in: Etiology and Triggering Factors, Supportive Care and Complication Management - [46]
Chrysostomou C, Faustini F, Segelmark M et al.. “A national cohort study examined the risk of severe infection and infection-related mortality in patients with chronic kidney disease with lupus nephritis in comparison to other chronic kidney disease etiologies.” Kidney international (2026). PMID: 41276017 ↗
L2bCOHORTCited in: Etiology and Triggering Factors, Differential Diagnosis - [47]
Nicholas SB, Nobakht N, Alicic RZ. “Therapeutic Considerations in Preventing Chronic Kidney Disease.” Annual review of medicine (2026). PMID: 41270289 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Supportive Care and Complication Management - [48]
Rani P, Nagaraju SP, Swaminathan SM et al.. “Prevalence and Predictors of Rapid Estimated Glomerular Filtration Rate Decline in Patients with Non-albuminuric Diabetic Kidney Disease: A Single-centre Retrospective Cohort Study.” The Nigerian postgraduate medical journal (2026). PMID: 41479184 ↗
L2bCOHORTCited in: Etiology and Triggering Factors, Clinical Features and Variants - [49]
Izarra A, Bermúdez-López M, Valdivielso JM et al.. “Baseline and 4-year associations between prediabetes and kidney impairment: Insights from the ILERVAS cohort.” Diabetes, obesity & metabolism (2026). PMID: 41705635 ↗
L5OTHERCited in: Etiology and Triggering Factors, Clinical Features and Variants, Guidelines and Resources - [50]
Hu Q, Chen L, Xing L et al.. “Association of remnant cholesterol with cardiovascular events and mortality in biopsy-proven diabetic kidney disease.” Frontiers in endocrinology (2026). PMID: 41685232 ↗
L5OTHERCited in: Etiology and Triggering Factors - [51]
Tian Q, Liu Y, Cao Q et al.. “The predictive potential of surrogate indicators of insulin resistance for type 2 diabetic kidney disease.” Frontiers in endocrinology (2026). PMID: 41675566 ↗
L5OTHERCited in: Etiology and Triggering Factors - [52]
Qin JL, Zhao J, Chen YL et al.. “Metabolic syndrome and diabetic kidney disease: a consistent dose-response association validated in an independent clinical cohort.” Frontiers in endocrinology (2025). PMID: 41659341 ↗
L5OTHERCited in: Etiology and Triggering Factors - [53]
Naik AS, Alakwaa FM, Nair V et al.. “Metabolic surgery mitigates early kidney injury in obese youth with diabetes by suppressing mTORC1/JAK/STAT signaling.” The Journal of clinical investigation (2026). PMID: 41665972 ↗
L2bTRIAL_NONRANDOMCited in: Pathophysiology - [54]
Wei T, Huang J, Wan B et al.. “Unveiling the Therapeutic Potential of Suyin Detoxification Prescription in Diabetic Nephropathy: A Comprehensive Study Integrating Clinical Efficacy, Network Pharmacology, and Molecular Mechanisms.” Journal of diabetes research (2025). PMID: 41497482 ↗
L1bRCTCited in: Pathophysiology - [55]
Zhang Y, Wang Y, Qiao Y et al.. “Targeting the NAD+-SIRT3 axis to mitigate metabolic memory in diabetic kidney disease.” Renal failure (2026). PMID: 41991506 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [56]
Cao W, Cao G, Meng Q et al.. “Integrative Insights Into Mitochondrial Dysfunction and Organelle Crosstalk in Diabetic Kidney Disease.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2026). PMID: 41863504 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [57]
Pandey A, Badruddeen, Akhtar J et al.. “Impact of angiopoietin-like 4 (ANGPTL4) protein and O-linked β-N-acetylglucosamine(O-GlcNAc) in diabetic nephropathy.” Diabetes research and clinical practice (2026). PMID: 41833781 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [58]
Shao N, Wang J, Liu J et al.. “Mitochondrial Dynamics in Diabetic Kidney Disease: Underlying Mechanisms and Novel Therapeutics.” International journal of molecular sciences (2026). PMID: 41828648 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [59]
He M, Wang Z, Miao Z et al.. “Post‑translational modifications in diabetic kidney disease (Review).” International journal of molecular medicine (2026). PMID: 41685570 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [60]
Zhang RM, Caramori ML. “Inflammation and Diabetic Kidney Disease.” International journal of molecular sciences (2026). PMID: 41596736 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [61]
Verma A, Upadhyay A. “Diabetic kidney disease, biomarkers, and finerenone.” Diabetes, obesity & metabolism (2026). PMID: 41555617 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology, Supportive Care and Complication Management - [62]
Yang K, Fang Y, He J et al.. “Adipokine networks in diabetic kidney disease: mechanistic insights and therapeutic implications.” Lipids in health and disease (2026). PMID: 41519764 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [63]
Xu Y, Wu X, Ge M et al.. “Soluble guanylate cyclase modulators-a novel therapeutic approach for diabetic kidney disease.” Renal failure (2025). PMID: 41485909 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [64]
Lee A. “Mouse Models of Diabetic Complications: Dissecting Molecular Mechanisms of Disease Progression.” Frontiers in bioscience (Landmark edition) (2026). PMID: 41914292 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [65]
Varda L, Vreča N, Ekart R et al.. “Diabetic Kidney Disease: From Pathophysiology to Treatment Perspectives.” Kidney & blood pressure research (2026). PMID: 41632731 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [66]
Husain-Syed F, Yuecel G, Daschner C et al.. “Therapeutic Advances in Diabetic Kidney Disease: 30 Years of Evidence and the Rise of the "Fantastic Four" in Nephrology.” Cardiorenal medicine (2026). PMID: 41528949 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [67]
Gong D, Chen X, Dong Z et al.. “Resveratrol inhibits renal ischemia and reperfusion injury in diabetes via reducing oxidative stress, inflammation, and apoptosis.” Renal failure (2026). PMID: 41958068 ↗
L5OTHERCited in: Pathophysiology, Supportive Care and Complication Management - [68]
Ni B, Yang Y, Yu B et al.. “Hirsutine mitigates high glucose-induced cell injury via autophagy activation and NRF2/GPX4-mediated ferroptosis inhibition.” Renal failure (2026). PMID: 41913060 ↗
L5OTHERCited in: Pathophysiology - [69]
Wang H, Guo J, Wang Q et al.. “ADAMTS13 ameliorates diabetic nephropathy by Nrf2/GPX4/eNOS signaling pathway.” Renal failure (2026). PMID: 41912450 ↗
L5OTHERCited in: Pathophysiology - [70]
Xia W, Wang M, Gao Y et al.. “Unveiling the TrkA-p35/CDK5 axis: a novel therapeutic target in diabetic kidney disease.” Frontiers in endocrinology (2026). PMID: 41907549 ↗
L5OTHERCited in: Pathophysiology - [71]
Wu Y, Fan L, You H et al.. “Qigui didang decoction alleviates renal injury in a diabetic kidney disease model with metabolic memory features: association with ferroptosis and the SIRT1/Nrf2 pathway.” Pharmaceutical biology (2026). PMID: 41874449 ↗
L5OTHERCited in: Pathophysiology - [72]
Li Y, Rao J, Lai W et al.. “IL-15 Links Muscle-Kidney Crosstalk to Preserving Podocyte Mitochondrial Fusion and Attenuating Diabetic Nephropathy.” Journal of cachexia, sarcopenia and muscle (2026). PMID: 41846397 ↗
L5OTHERCited in: Pathophysiology - [73]
Li W, Bai R, Gao X et al.. “MR Elastography in Diabetic Rats: Assessing Glomerular Hyperfiltration, Dapagliflozin Therapy Response, and Early Diabetic Nephropathy.” Journal of magnetic resonance imaging : JMRI (2026). PMID: 41840723 ↗
L5OTHERCited in: Pathophysiology - [74]
Lin WR, Huang TS, Chang HH et al.. “Kidney Effectiveness and Safety of Adding Spironolactone in Patients With Type 2 Diabetes Receiving Renin-Angiotensin System Inhibitors Therapy.” Clinical and translational science (2026). PMID: 41839821 ↗
L5OTHERCited in: Pathophysiology, Diagnosis and Workup, Prognosis and Long-term Outcomes, Special Populations - [75]
Aguilar-Cartes M, Opazo-Ríos L, Droguett A et al.. “SOCS1 Mimetic Peptide Enhances Empagliflozin Improvement on Kidney Damage in the Type 2 Diabetes Mouse Model BTBR ob/ob.” International journal of molecular sciences (2026). PMID: 41828692 ↗
L5OTHERCited in: Pathophysiology - [76]
Jelinčić Korčulanin M, Racetin A, Pavlović N et al.. “Connexin 43 and Pannexin 1 in Renal Cell Populations in Diabetic Kidney Disease.” International journal of molecular sciences (2026). PMID: 41828379 ↗
L5OTHERCited in: Pathophysiology, Special Populations - [77]
Hou Q, Huang G, Kan S et al.. “Acarbose ameliorates podocyte injury and glomerular lesions in diabetic nephropathy through USP46 activation.” Science translational medicine (2026). PMID: 41811985 ↗
L5OTHERCited in: Pathophysiology, Clinical Features and Variants - [78]
Jiang Y, Chang J, Guo Y et al.. “TangShenWeiNing formula alleviates diabetic kidney disease by inhibiting ferroptosis via AMPK pathway in renal tubular epithelial cells.” Frontiers in endocrinology (2026). PMID: 41767403 ↗
L5OTHERCited in: Pathophysiology - [79]
Novaes AS, Felizardo RJF, Camara NOS et al.. “Extracellular Vesicles Facilitate the Crosstalk Between High Glucose-Stimulated Mesangial Cells and Healthy Podocytes to Mediate Injury Responses.” International journal of molecular sciences (2026). PMID: 41752063 ↗
L5OTHERCited in: Pathophysiology - [80]
Liu S, Xie K, Zhao H et al.. “Aflatoxin B1 accelerates diabetic nephropathy progression via ITGA11/LTBP1-dependent oxidative and fibrotic pathways: Evidence from multi-omics and molecular simulations.” Chemico-biological interactions (2026). PMID: 41722833 ↗
L5OTHERCited in: Pathophysiology - [81]
Vatanparast RG, Aliyari M, Yazdi MP et al.. “Calebin A mitigates oxidative stress and inflammation in diabetic nephropathy via Nrf2/HO-1 and NF-κB signaling pathways.” Journal of diabetes investigation (2026). PMID: 41714879 ↗
L5OTHERCited in: Pathophysiology - [82]
AbdelMagid AM, Kamel AM, Farid SF. “Beyond Monotherapy: The Superior Efficacy of Combined GLP-1 Receptor Agonist and SGLT2 Inhibitors on Renal Biomarkers: A Systematic Review and Meta-Analysis.” Pharmacotherapy (2026). PMID: 41947610 ↗
L2aSR_OBSCited in: Clinical Features and Variants, Diagnosis and Workup - [83]
Passanisi S, Piona C, Mancioppi V et al.. “Optimal age, duration of diabetes and frequency of screening for diabetic nephropathy in children and youths with type 1 Diabetes: A systematic review.” Diabetes research and clinical practice (2026). PMID: 41371346 ↗
L2aSR_OBSCited in: Clinical Features and Variants - [84]
Heerspink HJL, Birkenfeld AL, Cherney DZI et al.. “Finerenone in Type 1 Diabetes and Chronic Kidney Disease.” The New England journal of medicine (2026). PMID: 41780000 ↗
L1bRCTCited in: Clinical Features and Variants, Diagnosis and Workup, Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations - [85]
Murakoshi M, Kamei N, Tanaka M et al.. “High-normal levels of B-type natriuretic peptide are associated with chronic kidney disease progression independent of albuminuria in individuals with diabetes: an observational cohort study.” Diabetes research and clinical practice (2026). PMID: 41747771 ↗
L2bCOHORTCited in: Clinical Features and Variants, Diagnosis and Workup, Prognosis and Long-term Outcomes, Special Populations - [86]
Makino H, Kasahara M, Takashima R et al.. “Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double-blind, placebo-controlled trial.” Diabetes, obesity & metabolism (2026). PMID: 41582689 ↗
L1bRCTCited in: Clinical Features and Variants - [87]
Mejía-Rodríguez O, Ávila-Díaz M, Prado-Uribe C et al.. “Short- and Middle-Term Nephroprotective and Cardioprotective Effects of Pentoxifylline in Patients with Diabetic Nephropathy: A Randomized Controlled Trial.” Medical sciences (Basel, Switzerland) (2026). PMID: 41562916 ↗
L1bRCTCited in: Clinical Features and Variants, Guidelines and Resources - [88]
Munoz Mendoza J, Weir MR, Anker SD et al.. “Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy.” Clinical journal of the American Society of Nephrology : CJASN (2026). PMID: 41533467 ↗
L1bRCTCited in: Clinical Features and Variants, Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence - [89]
Tanaka A, Vaduganathan M, Imai T et al.. “Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR).” Cardiovascular diabetology (2025). PMID: 41351003 ↗
L1bRCTCited in: Clinical Features and Variants, Prognosis and Long-term Outcomes - [90]
Mottl A, Scott C, Green JB et al.. “Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.” Journal of the American Society of Nephrology : JASN (2026). PMID: 41196655 ↗
L1bRCTCited in: Clinical Features and Variants - [91]
Arici M, Ates K, Yildiz A et al.. “Diabetes and chronic kidney disease in Turkey (DIAKIT): a cross-sectional cohort study.” BMC nephrology (2025). PMID: 41331919 ↗
L2bCOHORTCited in: Clinical Features and Variants - [92]
Katayama S, Anker SD, Zhu D et al.. “Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function.” Journal of diabetes and its complications (2026). PMID: 41289823 ↗
L1bRCTCited in: Clinical Features and Variants, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence - [93]
Chen K, Shao W, Zhang H. “Meta-analysis of the efficacy and safety of Finerenone in diabetic kidney disease.” Medicine (2026). PMID: 41578591 ↗
L2aSR_OBSCited in: Clinical Features and Variants, Prognosis and Long-term Outcomes - [94]
Meng L, Li Z, Xu L et al.. “Emerging technologies for early risk stratification and precision management of diabetic kidney disease: a multimodal framework integrating digital phenotypes and clinical biomarkers.” Frontiers in endocrinology (2025). PMID: 41585789 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Variants - [95]
Motawi TK, Sabry D, Ahmed NM et al.. “Association of GAS6, AXL, and GAS6-AS lncRNAs with nephropathy in Egyptian patients with type 2 diabetes mellitus: a case-control observational study.” Nutrition & diabetes (2025). PMID: 41233312 ↗
L3bCASE_CONTROLCited in: Clinical Features and Variants - [96]
Acharya A, Kotakala CMK, Kodanda Ramu B et al.. “Assessing Renoprotective Effects of Empagliflozin and Telmisartan Combination Therapy in Non-albuminuric Diabetic Nephropathy: A Retrospective Cohort Study.” Cureus (2025). PMID: 41625819 ↗
L2bCOHORTCited in: Clinical Features and Variants - [97]
Ahmed RM, Soliman AR, Mohammed A. “Vonoprazan attenuates proteinuria in diabetic kidney disease through potential direct renal mechanism.” Scientific reports (2025). PMID: 41271916 ↗
L1bRCTCited in: Clinical Features and Variants - [98]
Nugroho P, Lydia A, Soewondo P et al.. “Modulation of renal inflammation and tubular injury by calcitriol in patients with early diabetic kidney disease: a randomized controlled trial.” Annals of medicine (2025). PMID: 41145267 ↗
L1bRCTCited in: Clinical Features and Variants - [99]
Kaygusuz Y, Özbek DA, Erdut A et al.. “Urinary Biomarker Profiles Define Divergent Pathways in Albuminuric and Non-Albuminuric Diabetic Kidney Disease.” Kidney diseases (Basel, Switzerland) (2026). PMID: 41938379 ↗
L5OTHERCited in: Clinical Features and Variants - [100]
González-Luis A, Siverio-Morales O, Hernández-Carballo C et al.. “Inflammatory markers associated with albuminuria and early atherosclerosis in type 2 diabetic kidney disease: a cross-sectional study.” Frontiers in endocrinology (2026). PMID: 41837147 ↗
L5OTHERCited in: Clinical Features and Variants, Special Populations - [101]
Wang J, Yu L, Yin J et al.. “The association between low hemoglobin-to-red blood cell distribution width ratio and macroalbuminuria in diabetic kidney disease: evidence from NHANES and an external validation cohort.” Renal failure (2026). PMID: 41833328 ↗
L5OTHERCited in: Clinical Features and Variants, Special Populations - [102]
Zafar A, Scarlata C, Jaleel N. “Chronic kidney disease in type 2 diabetes in UK primary care: Testing frequency, coding accuracy and clinical inertia.” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 41677011 ↗
L5OTHERCited in: Clinical Features and Variants - [103]
Su J, Su J, Wang W et al.. “Low HDL cholesterol is associated with elevated TNFR1 and TNFR2 levels in early diabetic kidney disease.” Frontiers in endocrinology (2026). PMID: 41658514 ↗
L5OTHERCited in: Clinical Features and Variants - [104]
Cheng YW, Kao YW, Chen SW et al.. “Effect of SGLT2 inhibitors versus DPP4 inhibitors on major adverse kidney events in diabetic people with varied kidney function decline.” Frontiers in endocrinology (2025). PMID: 41625233 ↗
L5OTHERCited in: Clinical Features and Variants - [105]
Bahari H, Asadi Z. “Effects of Curcumin/Turmeric Supplementation on Kidney Function in Individuals With Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.” Endocrinology, diabetes & metabolism (2026). PMID: 41761990 ↗
L1aSR_MA_RCTCited in: Diagnosis and Workup - [106]
Wang Y, Liu X, Xiao Z. “The diagnostic value of immune-inflammatory markers for diabetic kidney disease in type 2 diabetic patients: a meta-analysis.” Frontiers in endocrinology (2026). PMID: 41958879 ↗
L2aSR_OBSCited in: Diagnosis and Workup - [107]
Tang Y, Li Z, Jia Z. “Systematic review of ocular and circulatory cytokines linking diabetic retinopathy to kidney disease.” Frontiers in endocrinology (2026). PMID: 41890176 ↗
L2aSR_OBSCited in: Diagnosis and Workup, Supportive Care and Complication Management - [108]
Dai B, Chen Y, Xiao Y et al.. “Efficacy and safety of Jinlida granules as an adjuvant treatment for diabetic nephropathy: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 41767388 ↗
L2aSR_OBSCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes - [109]
Goumboundi IA, Afrifa J, Ephraim RKD. “Association Between Monocyte-to-High-Density Lipoprotein Ratio and Diabetic Nephropathy: A Systematic Review and Meta-Analysis.” BioMed research international (2026). PMID: 41903155 ↗
L2aSR_OBSCited in: Diagnosis and Workup - [110]
Hong SH, Lee H, Lee SY et al.. “Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study.” BMJ open (2026). PMID: 41856597 ↗
L2bCOHORTCited in: Diagnosis and Workup, Special Populations - [111]
Yu L, Zhang Y, Sun C et al.. “Diabetic retinopathy severity is associated with renal function deterioration in patients with diabetic kidney disease: a retrospective cohort study.” Frontiers in endocrinology (2026). PMID: 41837122 ↗
L2bCOHORTCited in: Diagnosis and Workup, Supportive Care and Complication Management, Special Populations - [112]
Sabir S, Shahzad M, Malik UI et al.. “Effect of Mesenchymal Stem Cell Infusion in Stage II-IV Diabetic Nephropathy.” Journal of the College of Physicians and Surgeons--Pakistan : JCPSP (2026). PMID: 41792063 ↗
L1bRCTCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes, Special Populations - [113]
Ramadurgum P, Sharma K, Pinon A et al.. “GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes.” Current cardiology reports (2026). PMID: 41880122 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Supportive Care and Complication Management - [114]
Guo Y, Feng Y, Wu H et al.. “The Role of Non-Coding RNAs in the Pathogenesis and Progression of Diabetic Kidney Disease.” International journal of molecular sciences (2026). PMID: 41828573 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup - [115]
Rhee CM, Zisman-Ilani Y, Kalantar-Zadeh K et al.. “Continuous glucose monitoring in patients with chronic kidney disease on dialysis and with kidney transplantation.” Current opinion in nephrology and hypertension (2026). PMID: 41787610 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Supportive Care and Complication Management - [116]
Li Y, Yun D, Kwak SH et al.. “Urinary metabolomics identifies isoleucine as a prognostic biomarker for progression of diabetic kidney disease.” Frontiers in endocrinology (2026). PMID: 41948556 ↗
L5OTHERCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes, Special Populations - [117]
Lu L, Gu Q, Zheng Y et al.. “Incremental peritoneal dialysis preserves residual renal function in diabetic end-stage kidney disease.” Renal failure (2026). PMID: 41914033 ↗
L5OTHERCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes, Special Populations - [118]
Wang Y, Chen W, Xiong X et al.. “Plasma R-spondin 2 levels are associated with the progression of diabetic kidney disease.” Frontiers in endocrinology (2026). PMID: 41907558 ↗
L5OTHERCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes, Special Populations - [119]
Wong K, Pitcher D, Barratt J et al.. “Association of UACR and UPCR with kidney failure: analysis of observational data in patients with rare kidney diseases.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 41894233 ↗
L5OTHERCited in: Diagnosis and Workup - [120]
Jiang T, Deng J, Hu X et al.. “Integrated multi-omics analysis unveils microbiota-metabolite-host interactions and novel biomarkers for early diabetic kidney disease diagnosis.” Frontiers in immunology (2026). PMID: 41878445 ↗
L5OTHERCited in: Diagnosis and Workup, Special Populations - [121]
Li L, Ma F, Bao C et al.. “Development and validation of a multivariable prediction model for non-invasive discrimination between diabetic and non-diabetic kidney disease in type 2 diabetes: a clinical nomogram.” Frontiers in endocrinology (2026). PMID: 41869042 ↗
L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis, Prognosis and Long-term Outcomes, Special Populations - [122]
Mourya B, Sangha SS, Kumar A et al.. “Effect of intravitreal bevacizumab on kidney function and proteinuria among diabetic patients: a prospective observational study in Asian population.” Renal failure (2026). PMID: 41851996 ↗
L5OTHERCited in: Diagnosis and Workup, Special Populations - [123]
Li Y, Qin Z, Si T et al.. “Correlation between serum prolactin and the systemic immune-inflammation index in diabetic kidney disease: a cross-sectional study.” Frontiers in endocrinology (2026). PMID: 41847444 ↗
L5OTHERCited in: Diagnosis and Workup, Special Populations - [124]
de la Rambelje MA, Beldhuis IE, Heerspink HJL et al.. “Protein profiles and associated biological pathways among different aetiologies of chronic kidney disease: new insights from DAPA-CKD.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 40920470 ↗
L1bRCTCited in: Differential Diagnosis, Landmark Trials and Key Evidence - [125]
Garmaa G, Nagy R, Kói T et al.. “Panel miRNAs are potential diagnostic markers for chronic kidney diseases: a systematic review and meta-analysis.” BMC nephrology (2024). PMID: 39138396 ↗
L2aSR_OBSCited in: Differential Diagnosis - [126]
Zhao Y, Liu L, Zuo L et al.. “A Novel Risk Score Model for the Differential Diagnosis of Type 2 Diabetic Nephropathy: A Multicenter Study.” Journal of diabetes research (2023). PMID: 38155834 ↗
L1bRCTCited in: Differential Diagnosis - [127]
Wang W, Guo W, Xu X et al.. “A rare case of sero-negative anti-glomerular basement membrane disease combined with diabetic nephropathy and literature review.” Renal failure (2025). PMID: 40785208 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [128]
Wang X, Chen L, Shi K et al.. “Diabetes and chronic kidney disease in Chinese adults: a population-based cohort study.” BMJ open diabetes research & care (2024). PMID: 38267203 ↗
L2bCOHORTCited in: Differential Diagnosis - [129]
Hustrini NM, Susalit E, Widjaja FF et al.. “The Etiology of Advanced Chronic Kidney Disease in Southeast Asia: A Meta-analysis.” Journal of epidemiology and global health (2024). PMID: 38587764 ↗
L2aSR_OBSCited in: Differential Diagnosis - [130]
Patel CA, Patel S, Patel S et al.. “Targeting TRPC6 in podocytopathies: Why clinical translation remains a challenge?” Pharmacological reports : PR (2026). PMID: 40719843 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [131]
Lee-Boey JS, Tan JK, Lim ZF et al.. “Obesity-related glomerulopathy: How it happens and future perspectives.” Diabetic medicine : a journal of the British Diabetic Association (2025). PMID: 40226862 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [132]
Zachariah T, Radhakrishnan J. “Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease.” Clinical journal of the American Society of Nephrology : CJASN (2024). PMID: 39037799 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [133]
Liu Y, Xu K, Xiang Y et al.. “Role of MCP-1 as an inflammatory biomarker in nephropathy.” Frontiers in immunology (2023). PMID: 38239353 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [134]
Zhan HQ, Zhang X, Chen XL et al.. “Application of nanotechnology in the treatment of glomerulonephritis: current status and future perspectives.” Journal of nanobiotechnology (2024). PMID: 38169389 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [135]
Weerasooriya L, Howie AJ, Wakeman MP et al.. “Kidney biopsy findings in children with diabetes mellitus.” Pediatric nephrology (Berlin, Germany) (2024). PMID: 38123711 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [136]
Juha M, Molnár A, Jakus Z et al.. “NETosis: an emerging therapeutic target in renal diseases.” Frontiers in immunology (2023). PMID: 37744367 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [137]
Oshima Y, Sawa N, Yamanouchi M et al.. “Clinicopathological cohort study of kidney biopsy findings resulting in dialysis during long-term follow-up exceeding 30 years.” Clinical and experimental nephrology (2025). PMID: 40434507 ↗
L2bCOHORTCited in: Differential Diagnosis - [138]
Shaheen M, Bharat A, Friedman AN et al.. “ALECT2 amyloidosis with concurrent IgG4-related interstitial nephritis, membranous nephropathy and diabetic kidney disease: a case report and literature review.” Journal of nephrology (2024). PMID: 38630340 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [139]
Hu J, Liang Y, Sun K et al.. “Diabetes mellitus with anti-glomerular basement membrane disease and anti-tubular basement membrane disease: a rare case report of reversible dialysis dependence.” Frontiers in immunology (2025). PMID: 41601656 ↗
L4CASE_REPORTCited in: Differential Diagnosis, Supportive Care and Complication Management - [140]
Chen G, Wang Y, Zhang L et al.. “Research progress on miR-124-3p in the field of kidney disease.” BMC nephrology (2024). PMID: 39112935 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [141]
Dybiec J, Frąk W, Kućmierz J et al.. “Liquid Biopsy: A New Avenue for the Diagnosis of Kidney Disease: Diabetic Kidney Disease, Renal Cancer, and IgA Nephropathy.” Genes (2024). PMID: 38254967 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [142]
Li Z, Han Y, Yuan S et al.. “Clinicopathological characteristics and outcomes in patients with diabetic nephropathy coexisting idiopathic membranous nephropathy: a retrospective observational study.” Renal failure (2026). PMID: 41820026 ↗
L5OTHERCited in: Differential Diagnosis - [143]
Zhang H, Lou K, Qian L et al.. “CKAP4 in Extracellular Vesicle-Derived From Podocyte Serves as a Non-Invasive Diagnostic Biomarker for Diabetic Nephropathy and Promotes Vascular Calcification.” Journal of extracellular vesicles (2025). PMID: 41316993 ↗
L5OTHERCited in: Differential Diagnosis - [144]
Lin L, Yan L, Li N et al.. “Reliable biomarkers for diabetic nephropathy using machine learning-assisted contrast-enhanced ultrasonography and clinical characteristics.” Clinical and experimental medicine (2025). PMID: 41171478 ↗
L5OTHERCited in: Differential Diagnosis - [145]
Yang X, Tang W, Chan H et al.. “Genetic evidence for repurposing GLP-1 receptor agonists in chronic kidney disease and IgA nephropathy: Metabolic and anti-inflammatory pathways beyond glycaemic control.” Diabetes, obesity & metabolism (2025). PMID: 40994081 ↗
L5OTHERCited in: Differential Diagnosis - [146]
Conserva F, Pesce F, Cinefra C et al.. “A renal biopsy-anchored multi-marker signature involving AOPEP SNP-driven splicing, miR-27b-3p and glycated albumin for stratifying renal damage in type 2 diabetes.” Diabetes research and clinical practice (2025). PMID: 40934963 ↗
L5OTHERCited in: Differential Diagnosis - [147]
Mu F, Bai X, Bai X et al.. “Analysis of pathological spectrum characteristics in elderly patients with nephrotic syndrome: a comparative study with non-elderly patients.” Renal failure (2025). PMID: 40803348 ↗
L5OTHERCited in: Differential Diagnosis - [148]
Wu M, Zhou X, Chen S et al.. “The alternations of gut microbiota in diabetic kidney disease: insights from a triple comparative cohort.” Frontiers in cellular and infection microbiology (2025). PMID: 40654567 ↗
L5OTHERCited in: Differential Diagnosis - [149]
Yin T, Yang L, Tang L et al.. “Podocyte FFAR4 deficiency aggravated glomerular diseases and aging.” Molecular therapy : the journal of the American Society of Gene Therapy (2025). PMID: 40450519 ↗
L5OTHERCited in: Differential Diagnosis - [150]
Abe M, Niioka H, Matsumoto A et al.. “Self-Supervised Learning for Feature Extraction from Glomerular Images and Disease Classification with Minimal Annotations.” Journal of the American Society of Nephrology : JASN (2025). PMID: 40029749 ↗
L5OTHERCited in: Differential Diagnosis - [151]
Kitamura H, Tanaka S, Hiyamuta H et al.. “Associations of Causes of Chronic Kidney Disease with Disease Progression and Mortality: Insights from the Fukuoka Kidney Disease Registry Study.” American journal of nephrology (2025). PMID: 39778545 ↗
L5OTHERCited in: Differential Diagnosis - [152]
Fountoulakis N, Pavlou P, Stathi D et al.. “Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial.” Diabetes, obesity & metabolism (2026). PMID: 41705420 ↗
L1bRCTCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations - [153]
Wexler DJ, Mayberry LS, Nelson LA et al.. “Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial.” American heart journal (2026). PMID: 41456635 ↗
L1bRCTCited in: Supportive Care and Complication Management - [154]
Lado-Abeal J, Gude F, Ginzo-Villamayor MJ et al.. “Impact of specialised endocrinology care on metabolic control and healthcare utilisation outcomes after kidney transplantation in patients with diabetes: A 12-month observational cohort study.” Diabetes, obesity & metabolism (2026). PMID: 41725429 ↗
L2bCOHORTCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations - [155]
Cao Y, Li S, Li X et al.. “Association Between Diabetes-Related Lower-Extremity Amputations and Renal Function: An Observational, Single-Center, Retrospective Cohort Study.” The Journal of surgical research (2026). PMID: 41349163 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [156]
Erzeel J, van Es M, Mullens W et al.. “Evolving Mineralocorticoid Receptor Antagonism: a Narrative Review on Differences between Steroidal MRAs, Non-Steroidal MRAs and Aldosterone Synthase Inhibitors in Cardiorenal Disease.” Current heart failure reports (2026). PMID: 41615644 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [157]
Ntelis S, Wojeck BS. “Obesity Medications Beyond Glucose Control and Weight Reduction: Updates on the Expanding Benefits, Clinical Challenges, and Future Directions.” Current hypertension reports (2025). PMID: 41460420 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [158]
Wang Y, Zhang Y, Jin Q et al.. “The role of mitochondrial-associated endoplasmic reticulum membranes (MAMs) in diabetic microvascular complications: a review.” Cell death & disease (2025). PMID: 41366202 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [159]
Rykova E, Shmakova E, Damarov I et al.. “Non-Coding RNA in Type 2 Diabetes Cardio-Renal Complications and SGLT2 Inhibitor Response.” International journal of molecular sciences (2025). PMID: 41303682 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [160]
Chen ZH, Li D, Zhang JY et al.. “SUMOylation and NEDDylation in kidney diseases.” Experimental and molecular pathology (2025). PMID: 41273879 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [161]
Yuan D, Vangaveti VN, Arojojoye OA et al.. “Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Mellitus: A Retrospective Study.” Journal of diabetes research (2025). PMID: 41246137 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [162]
Murata A, Tanaka M, Takayoshi M et al.. “Osmotic nephropathy as a potentially underrecognized cause of acute kidney injury during SGLT2 inhibitor therapy: a case report and literature review.” CEN case reports (2026). PMID: 41501207 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [163]
Raza SA, Rehman AU, Aamir AH et al.. “Comparative efficacy and safety of finerenone in diabetic kidney disease: a meta-analysis of Asian and non-Asian populations.” BMC nephrology (2025). PMID: 41272492 ↗
L2aSR_OBSCited in: Prognosis and Long-term Outcomes - [164]
Ma J, Su Q, Wang H et al.. “Efficacy and Safety of Finerenone Combined with Dapagliflozin in the Treatment of Non-Diabetic Chronic Kidney Disease: A Single-Center Retrospective Study.” Drug design, development and therapy (2026). PMID: 41878680 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [165]
Tsai HJ, Yu PS, Hung WW et al.. “Trajectories of short-chain fatty acids and risk of adverse kidney outcomes in type 2 diabetes: a prospective cohort study.” Postgraduate medicine (2026). PMID: 41789569 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [166]
Yu Y, Yu J, Li J et al.. “The Prognostic Nutritional Index and Glycemic Status Synergistically Predict Early Renal Function Decline in Type 2 Diabetes: A Community-Based Cohort Study.” Nutrients (2026). PMID: 41683219 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [167]
Li L, Bao J, Zheng Y et al.. “Effect of Luteolin Supplementation on Kidney Damage and Long-Term Prognosis in Diabetic Patients: A Cohort Study.” Phytotherapy research : PTR (2026). PMID: 41493853 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [168]
Liu Y, Hu X, Jia J. “Adjunctive nutritional intervention improves glycaemia and quality of life in dapagliflozin-treated diabetic patients.” Pakistan journal of pharmaceutical sciences (2026). PMID: 41482798 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes - [169]
Han Y, Mao R, Xiong C et al.. “Development and external validation of a machine learning model for predicting in-hospital mortality in ICU patients with diabetic kidney disease: a study utilizing the MIMIC database and a Chinese cohort.” Frontiers in endocrinology (2026). PMID: 41837124 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes, Special Populations - [170]
Moedt E, Coca SG, Edwards K et al.. “Baseline Risk and Longitudinal Changes in kidneyintelX.dkd and Its Association With Kidney Outcomes in the CANVAS and CREDENCE Trials.” Diabetes care (2026). PMID: 41217780 ↗
L1bRCTCited in: Landmark Trials and Key Evidence, Guidelines and Resources - [171]
Januzzi JLJ, Sattar N, Vaduganathan M et al.. “A validated multivariable machine learning model to predict cardio-kidney risk in diabetic kidney disease.” Cardiovascular diabetology (2025). PMID: 40375260 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [172]
Li P, Zheng H, Ma J et al.. “Impact of finerenone on chronic kidney disease progression in Chinese patients with type 2 diabetes: a FIGARO-DKD subgroup analysis.” Frontiers in endocrinology (2025). PMID: 40370775 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [173]
Beal B, Buizen L, Yeung EK et al.. “Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: insights from the CREDENCE trial.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 40036884 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [174]
Siriwardana A, Buizen L, Jun M et al.. “Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial.” Diabetes, obesity & metabolism (2025). PMID: 39781601 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [175]
Ferrannini E, Baldi S, Scozzaro MT et al.. “Fasting substrates predict chronic kidney disease progression in CREDENCE trial patients with type 2 diabetes.” JCI insight (2024). PMID: 39704168 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [176]
de Vries ST, Pena MJ, Tye SC et al.. “Sex differences in the efficacy of angiotensin receptor blockers on kidney and cardiovascular outcomes among individuals with type 2 diabetes and diabetic kidney disease: post hoc analyses of the RENAAL and IDNT trials.” Diabetologia (2025). PMID: 39656268 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [177]
Mahaffey KW, Tuttle KR, Arici M et al.. “Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.” European heart journal (2025). PMID: 39211948 ↗
L1bRCTCited in: Landmark Trials and Key Evidence, Guidelines and Resources - [178]
Cardoza K, Kang A, Smyth B et al.. “Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial.” Diabetes, obesity & metabolism (2024). PMID: 38895796 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [179]
McEwan P, Gabb PD, Davis JA et al.. “The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 38730538 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [180]
Januzzi JL, Liu Y, Sattar N et al.. “Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial.” American heart journal (2024). PMID: 38401646 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [181]
. “Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.” The lancet. Diabetes & endocrinology (2024). PMID: 38061372 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [182]
Eissing T, Goulooze SC, van den Berg P et al.. “Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.” Diabetes, obesity & metabolism (2024). PMID: 38037539 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [183]
Koya D, Anker SD, Ruilope LM et al.. “Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis.” American journal of nephrology (2023). PMID: 37708857 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [184]
Mohebi R, Liu Y, Hansen MK et al.. “Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial.” Cardiovascular diabetology (2023). PMID: 37438734 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [185]
van der Hoek S, Jongs N, Oshima M et al.. “Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial.” Clinical journal of the American Society of Nephrology : CJASN (2023). PMID: 36999981 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [186]
Sarafidis P, Agarwal R, Pitt B et al.. “Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.” Clinical journal of the American Society of Nephrology : CJASN (2023). PMID: 36927680 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [187]
Yi TW, Smyth B, Di Tanna GL et al.. “Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2023). PMID: 36889425 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [188]
Bramlage P, Lanzinger S, Mühldorfer S et al.. “An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria.” Cardiovascular diabetology (2023). PMID: 37158855 ↗
L2bTRIAL_NONRANDOMCited in: Landmark Trials and Key Evidence - [189]
Dai ZC, Chen JX, Zou R et al.. “Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease.” Frontiers in immunology (2023). PMID: 37809091 ↗
L2aSR_OBSCited in: Landmark Trials and Key Evidence - [190]
Delanaye P, Scheen AJ. “[EMPA-KIDNEY: empagliflozin in chronic kidney disease].” Revue medicale de Liege (2023). PMID: 36634063 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [191]
Schaefer F, Montini G, Kang HG et al.. “Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies.” Trials (2024). PMID: 38509517 ↗
L2bTRIAL_NONRANDOMCited in: Landmark Trials and Key Evidence - [192]
Yi TW, Atiquzzaman M, Zheng Y et al.. “Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study.” Canadian journal of kidney health and disease (2022). PMID: 36578697 ↗
L2bCOHORTCited in: Landmark Trials and Key Evidence - [193]
Neuen BL, Heerspink HJL, Vart P et al.. “Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.” Circulation (2024). PMID: 37952217 ↗
L4CASE_REPORTCited in: Landmark Trials and Key Evidence - [194]
Moedt E, Ju W, Nair V et al.. “Novel protein biomarkers for risk stratification and personalized medicine.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 41874429 ↗
L5OTHERCited in: Landmark Trials and Key Evidence - [195]
Rayner B, Mahaffey KW, Mann JFE et al.. “Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 41728915 ↗
L5OTHERCited in: Landmark Trials and Key Evidence - [196]
Mir R, Elfaki I, Almassabi RF et al.. “Identification of novel genomic variants in diabetic nephropathy patients using whole-exome sequencing: a pilot investigation.” Frontiers in endocrinology (2026). PMID: 41970998 ↗
L5OTHERCited in: Special Populations - [197]
Yang S, Liu S, Ma Y et al.. “Real-world performance of open-source large language models in diabetes diagnosis.” Frontiers in endocrinology (2026). PMID: 41958877 ↗
L5OTHERCited in: Special Populations - [198]
Adamczak M, Kurnatowska I, Naumnik B et al.. “Pharmacological Nephroprotection in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus-Clinical Practice Position Statement of the Polish Society of Nephrology.” International journal of molecular sciences (2024). PMID: 39684653 ↗
L1cGUIDELINECited in: Guidelines and Resources - [199]
Dasgupta I, Zac-Varghese S, Chaudhry K et al.. “Current management of chronic kidney disease in type-2 diabetes-A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) guidelines.” Diabetic medicine : a journal of the British Diabetic Association (2025). PMID: 39415639 ↗
L1cGUIDELINECited in: Guidelines and Resources - [200]
Zac-Varghese S, Mark P, Bain S et al.. “Clinical practice guideline for the management of lipids in adults with diabetic kidney disease: abbreviated summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2024.” BMC nephrology (2024). PMID: 38971750 ↗
L1cGUIDELINECited in: Guidelines and Resources - [201]
Sugawara Y, Kanda E, Hamano T et al.. “Guidelines for clinical evaluation of chronic kidney disease in early stages : AMED research on regulatory science of pharmaceuticals and medical devices.” Clinical and experimental nephrology (2024). PMID: 38970650 ↗
L1cGUIDELINECited in: Guidelines and Resources - [202]
Almatham KI, Almudaiheem HY, Alhazzani WA et al.. “Saudi Clinical Practice Guidelines for management of diabetic kidney disease in adults.” Saudi medical journal (2025). PMID: 41087076 ↗
L1cGUIDELINECited in: Guidelines and Resources - [203]
Montero N, Oliveras L, Martínez-Castelao A et al.. “Clinical Practice Guideline for detection and management of diabetic kidney disease: A consensus report by the Spanish Society of Nephrology.” Nefrologia (2025). PMID: 40222774 ↗
L1cGUIDELINECited in: Guidelines and Resources - [204]
Mosenzon O, Raz I, Wiviott SD et al.. “Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.” Diabetes care (2022). PMID: 35997319 ↗
L1bRCTCited in: Guidelines and Resources - [205]
Spasovski G, Markovska ZS, Gjorgjievski N et al.. “Diabetic Kidney Disease Position Paper of the Macedonian Society of Nephrology, Dialysis, Transplantation and Artificial Organs (MSNDTAO), Macedonian Society of Cardiology (MSC), and Scientific Association of Endocrinologists and Diabetologists of Macedonia (SAEDM).” Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki) (2024). PMID: 39667008 ↗
L1cGUIDELINECited in: Guidelines and Resources - [206]
. “[National technical guidelines for the prevention and treatment of diabetic kidney disease in primary care (2023)].” Zhonghua nei ke za zhi (2023). PMID: 38044065 ↗
L1cGUIDELINECited in: Guidelines and Resources - [207]
Xu X, Zhao X, Ding Y et al.. “Effects of Intensive Systolic Blood Pressure Control on Kidney Outcomes in Patients With and Without CKD: A Post Hoc Analysis of SPRINT and ACCORD-BP Trials.” Journal of diabetes (2025). PMID: 41117098 ↗
L1bRCTCited in: Guidelines and Resources - [208]
Thiab S, Akhal T, Akeblersane M et al.. “Microvascular complications in prediabetes: a systematic review & meta-analysis.” Diabetes research and clinical practice (2025). PMID: 40419194 ↗
L2aSR_OBSCited in: Guidelines and Resources - [209]
Makvandi K, Eliasson B, Carlsen HK et al.. “Burden and Excess Risk of Adverse Outcomes in Patients With Type 1 Diabetes Using KDIGO Classification: A National Cohort Study.” Diabetes care (2025). PMID: 39565836 ↗
L2bCOHORTCited in: Guidelines and Resources - [210]
Plattner C, Sallaberger S, Bohn JP et al.. “Rationale and design of the Innsbruck Diabetic Kidney Disease Cohort (IDKDC)-a prospective study investigating etiology and progression of early-stage chronic kidney disease in type 2 diabetes.” Clinical kidney journal (2024). PMID: 38726211 ↗
L2bCOHORTCited in: Guidelines and Resources - [211]
Nicholas SB, Correa-Rotter R, Desai NR et al.. “First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting.” Journal of nephrology (2024). PMID: 39340711 ↗
L2bTRIAL_NONRANDOMCited in: Guidelines and Resources - [212]
Zhang Y, Singh P, Ganapathy K et al.. “Efficacy of continuous glucose monitoring in people living with diabetes and end stage kidney disease on dialysis: a systematic review.” BMC nephrology (2024). PMID: 39455937 ↗
L2aSR_OBSCited in: Guidelines and Resources - [213]
Levin-Iaina N, El'Nasasra H, Reiner-Benaim A. “Real-world implementation of the 2020 KDIGO guidelines for diabetes management in chronic kidney disease: a single-center retrospective study.” Frontiers in nephrology (2025). PMID: 41031090 ↗
L2bCOHORTCited in: Guidelines and Resources - [214]
. “11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026.” Diabetes care (2026). PMID: 41358881 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources - [215]
Guarino S, Iafusco D, Di Sessa A et al.. “Acidosis at Diagnosis of Type 1 Diabetes Mellitus: Relation With Kidney Function.” Pediatric diabetes (2025). PMID: 41293549 ↗
L5OTHERCited in: Guidelines and Resources - [216]
Fernandez-Fernandez B, Hasegawa T, Saruta Y et al.. “Plasma Interleukin 22 Predicts Progression of Early Diabetic Kidney Disease.” American journal of nephrology (2025). PMID: 40920595 ↗
L5OTHERCited in: Guidelines and Resources - [217]
Driendl S, Stadler S, Baumert M et al.. “Nocturnal hypoxemic burden is associated with worsening prognosis of chronic kidney disease in patients with type 2 diabetes.” Cardiovascular diabetology (2025). PMID: 40887593 ↗
L5OTHERCited in: Guidelines and Resources - [218]
Kalhan TA, Luo M, Chai JH et al.. “Health economic evaluation of a risk-stratified intervention in diabetic kidney disease.” Diabetologia (2025). PMID: 40739365 ↗
L5OTHERCited in: Guidelines and Resources - [219]
Melsom T, Brobak KM, Norvik JV et al.. “Iohexol clearance, but not estimated GFR, reveals a steeper GFR decline in patients with prediabetes.” Kidney international (2025). PMID: 40645290 ↗
L5OTHERCited in: Guidelines and Resources - [220]
Mohamed S, Lipscombe LL, Lipscombe J et al.. “Prevalence of diabetic kidney disease by world region of birth among immigrants and long-term residents of Canada with type 2 diabetes.” Diabetes research and clinical practice (2025). PMID: 40639770 ↗
L5OTHERCited in: Guidelines and Resources - [221]
Wanner C, Zhao MH, Amin AN et al.. “Guideline-Recommended Disease-Modifying Therapies for Patients with Cardiorenal Disease: A Call-to-Action Narrative Review.” Advances in therapy (2025). PMID: 40434618 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources